Rennova Health (RNVA) 10-Q 15 Nov 21 2021 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2021	Nov. 10, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2021
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-35141
Entity Registrant Name	RENNOVA HEALTH, INC.
Entity Central Index Key	0000931059
Entity Tax Identification Number	68-0370244
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	400 S. Australian Avenue
Entity Address, Address Line Two	Suite 800
Entity Address, City or Town	West Palm Beach
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33401
City Area Code	(561)
Local Phone Number	855-1626
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		13,491,000,000

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash	$ 331,491	$ 25,353
Accounts receivable, net	998,759	499,454
Receivable from related party	158,118
Inventory	280,762	445,415
Prepaid expenses and other current assets	151,938	148,522
Income tax refunds receivable	1,139,226	1,420,251
Current assets of discontinued operations		184,510
Total current assets	3,060,294	2,723,505
Property and equipment, net	7,060,539	7,814,435
Intangibles, net	259,443	259,443
Investments	9,016,072
Deposits	221,063	263,621
Right-of-use assets	877,412	1,000,272
Non-current assets of discontinued operations	5,014	200,815
Total assets	20,499,837	12,262,091
Current liabilities:
Accounts payable (includes related party amounts of $0.5 million and $0.3 million, respectively)	13,960,059	14,251,851
Checks issued in excess of bank account balance	79,518	84,760
Accrued expenses (includes related party amounts of $0.3 million and $0.2 million, respectively)	17,442,164	19,135,569
Income taxes payable	1,157,812	1,438,837
Current portion of notes payable	7,051,278	4,786,976
Current portion of note payable, related party	2,627,000	2,097,000
Current portion of finance lease obligations	220,461	249,985
Current portion of debentures	12,690,539	12,690,539
Current portion of right-of-use operating lease obligations	237,026	172,952
Derivative liabilities	455,336	455,336
Current liabilities of discontinued operations	1,447,967	3,814,245
Total current liabilities	57,369,160	59,178,050
Other liabilities:
Notes payable, net of current portion		1,196,256
Right-of-use operating lease obligations, net of current portion	640,386	827,320
Non-current liabilities of discontinued operations		78,217
Total liabilities	58,009,546	61,279,843
Commitments and contingencies
Stockholders’ deficit:
Common stock, $0.0001 par value, 10,000,000,000 shares authorized, 4,777,350,000 and 39,648 shares issued and outstanding, respectively	477,735	4
Additional paid-in-capital	1,233,162,879	819,498,236
Accumulated deficit	(1,271,170,696)	(868,536,506)
Total stockholders’ deficit	(37,509,709)	(49,017,752)
Total liabilities and stockholders’ deficit	20,499,837	12,262,091
Series H Preferred Stock [Member]
Stockholders’ deficit:
Series O preferred stock, $0.01 par value, 10,000 shares authorized, 5,500 and 0 shares issued and outstanding, respectively
Series F Preferred Stock [Member]
Stockholders’ deficit:
Series O preferred stock, $0.01 par value, 10,000 shares authorized, 5,500 and 0 shares issued and outstanding, respectively	17,500	17,500
Series L Preferred Stock [Member]
Stockholders’ deficit:
Series O preferred stock, $0.01 par value, 10,000 shares authorized, 5,500 and 0 shares issued and outstanding, respectively	2,500	2,500
Series M Preferred Stock [Member]
Stockholders’ deficit:
Series O preferred stock, $0.01 par value, 10,000 shares authorized, 5,500 and 0 shares issued and outstanding, respectively	208	220
Series N Preferred Stock [Member]
Stockholders’ deficit:
Series O preferred stock, $0.01 par value, 10,000 shares authorized, 5,500 and 0 shares issued and outstanding, respectively	110	294
Series O Preferred Stock [Member]
Stockholders’ deficit:
Series O preferred stock, $0.01 par value, 10,000 shares authorized, 5,500 and 0 shares issued and outstanding, respectively	$ 55

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Accounts payable, related parties, current	$ 0.5	$ 0.3
Accrued expenses related parties	$ 0.3	$ 0.2
Preferred stock par value	$ 0.01
Preferred stock shares authorized	5,000,000
Common stock par value	$ 0.0001	$ 0.0001
Common stock shares authorized	10,000,000,000	10,000,000,000
Common stock shares issued	4,777,350,000	39,648
Common stock shares outstanding	4,777,350,000	39,648
Series H Preferred Stock [Member]
Preferred stock par value		$ 0.01
Preferred stock shares authorized	14,202
Preferred stock shares outstanding	10	10
Series F Preferred Stock [Member]
Preferred stock par value	$ 0.01	$ 0.01
Preferred stock shares authorized	1,750,000	1,750,000
Preferred stock shares outstanding	1,750,000	1,750,000
Preferred stock shares issued	1,750,000	1,750,000
Series L Preferred Stock [Member]
Preferred stock par value	$ 0.01	$ 0.01
Preferred stock shares authorized	250,000	250,000
Preferred stock shares outstanding	250,000	250,000
Preferred stock shares issued	250,000	250,000
Series M Preferred Stock [Member]
Preferred stock par value	$ 0.01	$ 0.01
Preferred stock shares authorized	30,000	30,000
Preferred stock shares outstanding	20,810	22,000
Preferred stock shares issued	20,810	22,000
Series N Preferred Stock [Member]
Preferred stock par value	$ 0.01	$ 0.01
Preferred stock shares authorized	50,000	50,000
Preferred stock shares outstanding	11,084	29,434
Preferred stock shares issued	11,084	29,434
Series O Preferred Stock [Member]
Preferred stock par value	$ 0.01	$ 0.01
Preferred stock shares authorized	10,000	10,000
Preferred stock shares outstanding	5,500	0
Preferred stock shares issued	5,500	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Income Statement [Abstract]
Net revenues	$ 1,010,245	$ 1,950,698	$ 1,288,402	$ 5,860,807
Operating expenses:
Direct costs of revenues	1,207,749	2,805,829	4,074,149	8,151,478
General and administrative expenses	2,019,086	3,274,508	6,915,453	8,593,756
Depreciation and amortization	135,065	53,579	513,929	399,377
Total operating expenses	3,361,900	6,133,916	11,503,531	17,144,611
Loss from continuing operations before other income (expense) and income taxes	(2,351,655)	(4,183,218)	(10,215,129)	(11,283,804)
Other income (expense):
Other income (expense), net	(346,197)	169,101	4,140,049	6,907,670
Gain from extinguishment of debt	1,027,000	389,864	1,027,000	389,864
Gain (loss) from legal settlements	3,157,203	(23,652)	3,179,393	1,096,613
Interest expense	(700,786)	(2,377,980)	(2,503,173)	(7,926,750)
Total other income (expense), net	3,137,220	(1,842,667)	5,843,269	467,397
Net income (loss) from continuing operations before income taxes	785,565	(6,025,885)	(4,371,860)	(10,816,407)
Benefit from income taxes				(1,118,485)
Net income (loss) from continuing operations	785,565	(6,025,885)	(4,371,860)	(9,697,922)
Loss from discontinued operations	(31,388)	(166,180)	(423,791)	(164,293)
Gain on sale	576,787		11,303,939
Total income (loss) from discontinued operations	545,399	(166,180)	10,880,148	(164,293)
Net income (loss)	1,330,964	(6,192,065)	6,508,288	(9,862,215)
Deemed dividends	(259,530,999)	(63,544,950)	(409,142,478)	(66,695,318)
Net loss available to common stockholders	$ (258,200,035)	$ (69,737,015)	$ (402,634,190)	$ (76,557,533)
Net loss per share of common stock available to common stockholders- basic and diluted:
Continuing operations	$ (0.59)	$ (54,182.89)	$ (2.75)	$ (70,343.68)
Discontinued operations	0	(129.42)	0.07	(151.28)
Total basic and diluted	$ (0.59)	$ (54,312.31)	$ (2.68)	$ (70,494.96)
Weighted average number of shares of common stock outstanding during the period:
Basic and diluted	438,998,913	1,284	150,459,817	1,086

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 20,000		$ 510,402,293	$ (586,942,014)	$ (76,519,721)
Beginning balance, shares at Dec. 31, 2019	2,000,010	965
Conversions of Series I-2 Preferred Stock into common stock			25,000		25,000
Conversion of Series I-2 Preferred stock into common stock, shares		25
Net income (loss)				(5,791,778)	(5,791,778)
Ending balance, value at Mar. 31, 2020	$ 20,000		510,427,293	(592,733,792)	(82,286,499)
Ending balance, shares at Mar. 31, 2020	2,000,010	990
Beginning balance, value at Dec. 31, 2019	$ 20,000		510,402,293	(586,942,014)	(76,519,721)
Beginning balance, shares at Dec. 31, 2019	2,000,010	965
Net income (loss)					(9,862,215)
Ending balance, value at Sep. 30, 2020	$ 20,523		622,938,831	(663,499,547)	(40,540,193)
Ending balance, shares at Sep. 30, 2020	2,052,314	1,867
Beginning balance, value at Mar. 31, 2020	$ 20,000		510,427,293	(592,733,792)	(82,286,499)
Beginning balance, shares at Mar. 31, 2020	2,000,010	990
Exchange of Series K Preferred Stock for Series L Preferred Stock	$ (2,500)				(2,500)
Exchange of Series K Preferred Stock for Series L Preferred Stock, shares	(250,000)
Issuance of Series L Preferred Stock	$ 2,500				2,500
Issuance of Series L Preferred Stock, shares	250,000
Issuance of Series M Preferred Stock in exchange for related party loans and accrued interest	$ 220		21,999,780		22,000,000
Issuance of Series M Preferred Stock in exchange for related party loans and accrued interest, shares	22,000
Deemed dividend from issuance of Series M Preferred Stock				(3,150,368)	(3,150,368)
Net income (loss)				2,121,628	2,121,628
Ending balance, value at Jun. 30, 2020	$ 20,220		532,427,073	(593,762,532)	(61,315,239)
Ending balance, shares at Jun. 30, 2020	2,022,010	990
Conversions of Series N Preferred Stock into common stock	$ (1)		1
Conversion of Series N Preferred Stock into common stock, shares	(131)	589
Payment of cash in lieu of fractional shares			(684)		(684)
Deemed dividends from issuance of Series N Preferred Stock				(3,720,718)	(3,720,718)
Deemed dividends from trigger of down round provision features			59,824,232	(59,824,232)
Conversions of Series I-2 Preferred Stock into common stock			252,964		252,994
Conversion of Series I-2 Preferred stock into common stock, shares		288
Issuance of Series N Preferred Stock	$ 304		30,435,215		30,435,519
Issuance of Series N Preferred Stock, shares	30,435
Net income (loss)				(6,192,065)	(6,192,065)
Ending balance, value at Sep. 30, 2020	$ 20,523		622,938,831	(663,499,547)	(40,540,193)
Ending balance, shares at Sep. 30, 2020	2,052,314	1,867
Beginning balance, value at Dec. 31, 2020	$ 20,514	$ 4	819,498,236	(868,536,506)	(49,017,752)
Beginning balance, shares at Dec. 31, 2020	2,051,444	39,648
Conversions of Series N Preferred Stock into common stock	$ (42)	$ 44	(2)
Conversion of Series N Preferred Stock into common stock, shares	(4,177)	435,082
Deemed dividends			50,358,149	(50,358,149)
Net income (loss)				(3,893,994)	(3,893,994)
Ending balance, value at Mar. 31, 2021	$ 20,472	$ 48	869,856,383	(922,788,649)	(52,911,746)
Ending balance, shares at Mar. 31, 2021	2,047,267	474,730
Beginning balance, value at Dec. 31, 2020	$ 20,514	$ 4	819,498,236	(868,536,506)	(49,017,752)
Beginning balance, shares at Dec. 31, 2020	2,051,444	39,648
Net income (loss)					6,508,288
Ending balance, value at Sep. 30, 2021	$ 20,374	$ 477,735	1,233,162,879	(1,271,170,696)	(37,509,709)
Ending balance, shares at Sep. 30, 2021	2,037,404	4,777,350,000
Beginning balance, value at Mar. 31, 2021	$ 20,472	$ 48	869,856,383	(922,788,649)	(52,911,746)
Beginning balance, shares at Mar. 31, 2021	2,047,267	474,730
Exchange of Series M Preferred Stock into common stock	$ (6)	$ 45	(39)
Conversion of Series M Preferred Stock into common stock, shares	(620)	450,000
Conversions of Series N Preferred Stock into common stock	$ (89)	$ 907	(818)
Conversion of Series N Preferred Stock into common stock, shares	(8,888)	9,075,270
Issuance of Series O Preferred Stock	$ 28		2,499,972		2,500,000
Issuance of Series O Preferred stock, shares	2,750
Deemed dividends from trigger of down round provision features			99,253,330	(99,253,330)
Net income (loss)				9,071,318	9,071,318
Ending balance, value at Jun. 30, 2021	$ 20,405	$ 1,000	971,608,828	(1,012,970,661)	(41,340,429)
Ending balance, shares at Jun. 30, 2021	2,040,509	10,000,000
Exchange of Series M Preferred Stock into common stock	$ (6)	$ 9,500	(9,494)
Conversion of Series M Preferred Stock into common stock, shares	(570)	95,000,000
Conversions of Series N Preferred Stock into common stock	$ (53)	$ 467,235	(467,182)
Conversion of Series N Preferred Stock into common stock, shares	(5,285)	4,672,350,000
Issuance of Series O Preferred Stock	$ 28		2,499,972		2,500,000
Issuance of Series O Preferred stock, shares	2,750
Payment of cash in lieu of fractional shares			(244)		(244)
Deemed dividends from issuance of warrants under exchange agreement			341,525	(341,525)
Deemed dividends from extension of warrants			291,592	(291,592)
Deemed dividends from trigger of down round provision features			258,897,882	(258,897,882)
Issuance of Series L Preferred Stock, shares					950
Net income (loss)				1,330,964	$ 1,330,964
Ending balance, value at Sep. 30, 2021	$ 20,374	$ 477,735	$ 1,233,162,879	$ (1,271,170,696)	$ (37,509,709)
Ending balance, shares at Sep. 30, 2021	2,037,404	4,777,350,000

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Cash flows from operating activities:
Net loss from continuing operations	$ 785,565	$ (6,025,885)	$ (4,371,860)	$ (9,697,922)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	135,065	53,579	513,929	399,377
Amortization of debt discount and non-cash interest expense			113,552	108,958
Gain from extinguishment of debt			(1,027,000)	(389,864)
Loss on disposal of equipment			274,468	87,293
Net gain from legal settlements			(3,179,393)	(1,096,613)
Other income from federal government provider relief funds			(4,400,000)	(8,020,969)
Loss on sales of accounts receivable under sale agreements				591,563	$ (1,200,000)
Gain on sale of discontinued operations	(576,787)		(11,303,939)
Income (loss) from discontinued operations			10,880,148	(164,293)
Changes in operating assets and liabilities:
Accounts receivable			377,088	1,241,398
Inventory			164,653	(76,065)
Prepaid expenses and other current assets			(3,416)	(224,733)
Security deposits			42,558	(56,482)
Change in right-of-use assets			122,860	(941,116)
Accounts payable and checks issued in excess of bank balances			1,918,004	(1,163,944)
Accrued expenses			4,208,698	5,563,232
Change in right-of-use operating lease obligations			(122,860)	941,116
Income tax assets and liabilities				(522,885)
Net cash used in operating activities of continuing operations			(5,792,510)	(13,421,949)
Net cash provided by (used in) operating activities of discontinued operations			102,567	(100,685)
Net cash used in operating activities			(5,689,943)	(13,522,634)
Cash flows from investing activities:
Purchase of property and equipment				(370,890)
Net cash used in investing activities of continuing operations				(370,890)
Net cash used in investing activities of discontinued operations
Net cash used in investing activities				(370,890)
Cash flows from financing activities:
Proceeds from issuance of related party note payable and advances			890,000	5,809,553
Payments on related party note payable and advances			(360,000)	(4,187,387)
Payments of debentures				(920,000)
Proceeds from issuances of notes payable			1,245,000	1,198,835
Payments on notes payable			(350,508)	(1,552,748)
Receivable from related party			(158,118)
Proceeds from sale of accounts receivable under sales agreements				841,700
Receivables paid under accounts receivable sales agreements			(300,927)	(1,540,929)
Proceeds from issuance of Series O Preferred Stock			5,000,000
Federal government provider relief funds				12,542,691
Proceeds from Paycheck Protection Program notes payable				2,264,201
Cash paid for fractional shares in connection with reverse stock splits			(244)	(684)
Payments on capital lease obligations			(29,524)	(200,709)
Net cash provided by financing activities of continuing operations			5,935,679	14,254,523
Net cash provided by (used in) financing activities of discontinued operations			60,402	(157,589)
Net cash provided by financing activities			5,996,081	14,096,934
Net change in cash			306,138	203,410
Cash at beginning of period			25,353	16,933	16,933
Cash at end of period	$ 331,491	$ 220,343	$ 331,491	$ 220,343	$ 25,353

Organization and Summary of Sig

Organization and Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Organization and Summary of Significant Accounting Policies	Note 1 – Organization and Summary of Significant Accounting Policies Description of Business Rennova Health, Inc. (“Rennova”, together with its subsidiaries, the “Company”, “we”, “us” or “our”) is a provider of health care services. The Company owns one operating hospital in Oneida, Tennessee, a hospital located in Jamestown, Tennessee that it plans to reopen and operate, a physician’s office in Jamestown, Tennessee that it plans to reopen and a rural clinic in Kentucky. The Company’s operations consist of one business segment. Basis of Presentation The accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the consolidated financial statements as filed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, the unaudited condensed consolidated financial statements included herein contain all adjustments necessary to present fairly the Company’s consolidated financial position as of September 30, 2021, the results of its operations and changes in stockholders’ deficit for the three and nine months ended September 30, 2021 and 2020 and its cash flows for the nine months ended September 30, 2021 and 2020. Such adjustments are of a normal recurring nature. The results of operations for the nine months ended September 30, 2021 may not be indicative of results for the entire year ending December 31, 2021. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), include the accounts of Rennova and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in the consolidation. Comprehensive Income (Loss) During the three and nine months ended September 30, 2021 and 2020, comprehensive income (loss) was equal to the net income (loss) amounts presented in the accompanying unaudited condensed consolidated statements of operations. Reclassifications Certain items in the financial statements for the three and nine months ended September 30, 2020 were reclassified for comparison purposes. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of net revenues and expenses during the reporting period. Significant estimates and assumptions include the estimates of fair values of assets acquired and liabilities assumed in business combinations, including hospital acquisitions, the fair values of consideration received from the sale of subsidiaries, reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company’s deferred tax assets, the valuation of equity and derivative instruments, deemed dividends and debt discounts, among others. Actual results could differ from those estimates and would impact future results of operations and cash flows. Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents. Reverse Stock Splits On July 22, 2020, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-10,000 reverse stock split 1-for-1,000 reverse stock split As a result of the Reverse Stock Splits, every 10,000 shares of the Company’s common stock then outstanding was combined and automatically converted into one share of the Company’s common stock every 1,000 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock The par value and other terms of the common stock were not affected by the Reverse Stock Splits. The authorized capital of the Company of 10,000,000,000 5,000,000 Effective November 5, 2021, the Company increased the authorized shares of its common stock from 10,000,000,000 50,000,000,000 Sale of Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc. On June 25, 2021, the Company sold its subsidiaries, Health Technology Solutions, Inc. (“HTS”) and Advanced Molecular Services Group, Inc. (“AMSG”), including their subsidiaries, to InnovaQor, Inc. (“InnovaQor”), formerly known as VisualMED Clinical Solutions Corp. HTS and AMSG held Rennova’s software and genetic testing interpretation divisions. The financial results of HTS and AMSG, including the gain on sale, are reflected herein as discontinued operations. The sale is more fully discussed in Note 14. Revenue Recognition We recognize revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “ Revenue from Contracts with Customers (Topic 606),” ● The parties have approved the contract either in writing; orally by acknowledgement; or implicitly, based on customary business practices. ● Each party’s rights and the contract’s payment terms are identified. ● The contract has commercial substance. ● Collection is probable. We review our calculations for the realizability of gross revenues monthly to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payer groups and within our service offerings. The contractual allowance calculation is made based on historical allowance rates for the various specific payer groups monthly with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions, if any. This calculation is routinely analyzed by us based on actual allowances issued by payers and the actual payments made to determine what adjustments, if any, are needed. Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers and managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Our net revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Net revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect. Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain government programs, primarily Medicare, this is generally referred to as the “cost report” filing and settlement process). There were no adjustments to estimated Medicare and Medicaid reimbursement amounts and disproportionate-share funds related primarily to cost reports filed during the three and nine months ended September 30, 2021 and 2020. The Emergency Medical Treatment and Labor Act (“EMTALA”) requires any hospital participating in the Medicare program to conduct an appropriate medical screening examination of every person who presents to the hospital’s emergency room for treatment and, if the individual is suffering from an emergency medical condition, to either stabilize the condition or make an appropriate transfer of the individual to a facility able to handle the condition. The obligation to screen and stabilize emergency medical conditions exists regardless of an individual’s ability to pay for treatment. Federal and state laws and regulations require, and our commitment to providing quality patient care encourages, us to provide services to patients who are financially unable to pay for the health care services they receive. The federal poverty level is established by the federal government and is based on income and family size. The Company considers the poverty level in determining whether patients qualify for free or reduced cost of care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in net revenues. We provide discounts to uninsured patients who do not qualify for Medicaid or charity care. In implementing the uninsured discount policy, we may first attempt to provide assistance to uninsured patients to help determine whether they may qualify for Medicaid, other federal or state assistance, or charity care. If an uninsured patient does not qualify for these programs, the uninsured discount is applied. The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management’s assessment of historical write offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable (the “hindsight analysis”) as a primary source of information in estimating the collectability of our accounts receivable. We perform the hindsight analysis quarterly, utilizing rolling accounts receivable collection and write off data. We believe our quarterly updates to the estimated contractual allowance amounts and to the estimated implicit price concessions at each of our facilities provide reasonable estimates of our net revenues and valuation of our accounts receivable. For the three months ended September 30, 2021 and 2020, we recorded estimated contractual allowances of $ 6.8 14.0 1.9 2.2 16.2 32.9 6.2 6.2 Contractual Allowances and Doubtful Accounts Policy Accounts receivable are reported at realizable value, net of contractual allowances and estimated implicit price concessions (also referred to as doubtful accounts), which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimating and reviewing the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to contractual allowances and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may impact the receivables or reserve estimates. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts. Revisions to the allowances for doubtful accounts are recorded as an adjustment to revenues. As required by Topic 606, after estimated implicit price concessions and contractual and related allowance adjustments to revenues of $ 8.7 million and $ 16.2 million, respectively, for the three months ended September 30, 2021 and 2020, we reported net revenues of $ 1.0 million and $ 2.0 million, respectively. After estimated implicit price concessions and contractual and related allowance adjustments to revenues of $ 22.4 million and $ 39.1 million, respectively, for the nine months ended September 30, 2021 and 2020, we reported net revenues of $ 1.3 million and $ 5.9 million, respectively. We continue to review the provisions for implicit price concessions and contractual allowances. See Note 4 – Accounts Receivable and Income Tax Refunds Receivable. Leases in Accordance with ASU No. 2016-02 We account for leases in accordance with ASU No. 2016-02, Leases (Topic 842) Impairment or Disposal of Long-Lived Assets We account for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 360, Property, Plant and Equipment The Company did not record an asset impairment charge during the three and nine months ended September 30, 2021 and 2020. Fair Value Measurements We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk. We apply the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs that are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. We applied the Level 3 fair value hierarchy in determining the fair value of the InnovaQor Series B Preferred Stock on September 30, 2021 as more fully discussed in Note 14. Derivative Financial Instruments, Including the Adoption of ASU 2017-11 In July 2017, the FASB issued ASU 2017-11 “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings (loss) per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common stockholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). Deemed dividends represent the economic transfer of value to holders of equity-classified freestanding financial instruments when certain down round features (commonly referred to as “ratchets”) are present. The deemed dividends are presented as a reduction in net income or an increase in net loss available to common stockholders and a corresponding increase to additional paid-in-capital resulting in no change to stockholders’ equity/deficit. The incremental value of convertible debentures and warrants as a result of the down round provision features of $ 258.9 million and $ 59.8 million were recorded as deemed dividends for the three months ended September 30, 2021 and 2020, respectively. The incremental value of convertible debentures and warrants as a result of the down round provision features of $ 408.5 million and $ 59.8 million were recorded as deemed dividends for the nine months ended September 30, 2021 and 2020, respectively. In addition, we recorded deemed dividends during the three and nine months ended September 30, 2021 and 2020 as a result of: (i) the issuance of our Series M Convertible Redeemable Preferred Stock (the “Series M Preferred Stock”) on June 30, 2020; (ii) the issuance of warrants on August 27, 2021 in connection with the conversion of a portion of our Series M Preferred Stock; (iii) the issuance of our Series N Convertible Redeemable Preferred Stock (the “Series N Preferred Stock”) on August 31, 2020; and (iv) the extension of certain warrants during the three months ended September 30, 2021. Each of these transactions is more fully discussed in Note 11. See Note 10 for an additional discussion of derivative financial instruments. Income Taxes Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized. When projected future taxable income is insufficient to provide for the realization of deferred tax assets, the Company recognizes a valuation allowance. In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of September 30, 2021 and December 31, 2020. Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC Topic 260, “Earnings Per Share,” which establishes standards for computing and presenting earnings (loss) per share. Basic earnings (loss) per share of common stock is calculated by dividing net earnings (loss) available to common stockholders by the weighted-average shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted earnings (loss) per share is calculated by adjusting the weighted-average shares of common stock outstanding for the dilutive effect of common stock equivalents, including preferred stock, convertible debt, stock options and warrants outstanding for the period as determined using the treasury stock method. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation when their effect would be anti-dilutive. See Note 3 for the computation of the loss per share for the three and nine months ended September 30, 2021 and 2020.

Liquidity and Financial Conditi

Liquidity and Financial Condition	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity and Financial Condition	Note 2 – Liquidity and Financial Condition Jamestown Regional Medical Center Following an inspection at Jamestown Regional Medical Center it was determined that several conditions of participation in its Medicare agreement were deficient and the hospital failed to adequately correct the deficiencies. As a result, on June 12, 2019, Jamestown Regional Medical Center’s Medicare agreement was terminated. A significant percentage of patients at Jamestown Regional Medical Center are covered by Medicare and without any ability to get paid for these services, the Company suspended operations at the hospital. The Company plans to reopen the hospital upon securing adequate capital to do so. The reopening plans have also been disrupted by the coronavirus (“COVID-19”) pandemic and the timing of the reopening has been delayed and is now intended that the re-opening process will be initiated in 2022. Jellico Community Hospital Effective March 5, 2019, the Company acquired certain assets related to Jellico Community Hospital. On March 1, 2021, the Company closed Jellico Community Hospital, after the city of Jellico issued a 30-day termination notice for the lease of the building. The closure reduced operating losses and the monthly cash deficit for the Company. The collections of accounts receivable for the hospital were negatively impacted by the closure and resulted in a significant shortfall in the funds available to satisfy liabilities at the facility. Impact of the Pandemic COVID-19 was declared a global pandemic by the World Health Organization on March 11, 2020. We have been closely monitoring the COVID-19 pandemic and its impact on our operations and we have taken steps intended to minimize the risk to our employees and patients. These steps have increased our costs and our revenues have been significantly adversely affected. Demand for hospital services has substantially decreased. As more fully discussed in Note 6, we have received Paycheck Protection Program (“PPP”) loans. We have also received Health and Human Services (“HHS”) Provider Relief Funds from the federal government as more fully discussed below. If the COVID-19 pandemic continues for a further extended period, we expect to incur significant losses and additional financial assistance may be required. Going forward, the Company is unable to determine the extent to which the COVID-19 pandemic will continue to affect its business. The nature and effect of the COVID-19 pandemic on our balance sheet and results of operations will depend on the severity and length of the pandemic in our service areas; government activities to mitigate the pandemic’s effect; regulatory changes in response to the pandemic, especially those affecting rural hospitals; and existing and potential government assistance that may be provided. HHS Provider Relief Funds The Company received Provider Relief Funds from HHS provided to eligible healthcare providers out of the $ 100 billion Public Health and Social Services Emergency Fund provided for in the Coronavirus Aid, Relief and Economic Security Act (the “CARES Act”). The funds were allocated to eligible healthcare providers for expenses and lost revenue attributable to the COVID-19 pandemic. As of September 30, 2021, our facilities have received approximately $ 12.5 million in relief funds. The fund payments are grants, not loans, and HHS will not require repayment, but the funds must be used only for grant approved purposes. Based on an analysis of the compliance and reporting requirements of the Provider Relief Funds and the impact of the pandemic on our operating results through September 30, 2021, we have recognized $ 12.4 million of these funds as income as of September 30, 2021 of which $ 7.5 million and $ 0.5 million was recognized during the second and third quarters of 2020, respectively, and $ 2.5 million and $ 1.9 million was recognized as income during the first and second quarters of 2021, respectively. The remaining $ 0.1 million is included with PPP loans in the accompanying balance sheets. On September 19, 2020, HHS issued a Post-Payment Notice of Reporting Requirements (the “September 19, 2020 Notice”), which indicates that providers may recognize reimbursement for healthcare-related expenses, as defined therein, attributable to coronavirus that another source has not reimbursed and is not obligated to reimburse. Additionally, amounts received from HHS that are not fully expended on eligible healthcare-related expenses may be recognized as reimbursement for lost revenues, represented as a negative change in year-over-year net patient care operating income. Providers may apply payments to lost revenues up to the amount of the 2019 net gain from healthcare-related sources or, for entities that reported a negative net operating gain in 2019, receipts from HHS may be recognized up to a net zero gain/loss in 2020. On October 22, 2020, HHS issued an updated Post-Payment Notice of Reporting Requirements and a Reporting Requirements Policy Update (together, the “October 22, 2020 Notice”), which includes two primary changes: (1) the definition of lost revenue is changed to refer to the negative year-over-year difference in 2019 and 2020 actual revenue from patient care related sources as opposed to the negative year-over-year change in net patient care operating income, and (2) the definition of reporting entities is broadened to include the parent of one or more subsidiary tax identification numbers that received general distribution payments, entities having providers associated with it that provide diagnoses, testing or treatment for cases of COVID-19, or entities that can otherwise attest to the terms and conditions. As codified in the October 22, 2020 Notice, the Company’s estimate of pandemic relief funds that do not have to be reimbursed includes the allocation of certain general funds among subsidiaries. Regarding the amended definition of lost revenues, such change served to increase amounts eligible to be recognized as income, as compared to the September 19, 2020 Notice. As evidenced by the October 22, 2020 Notice, HHS’ interpretation of the underlying terms and conditions of such payments, including auditing and reporting requirements, continues to evolve. On January 15, 2021, the government issued “General and Targeted Distribution Post-Payment Notice of Reporting Requirements,” (the “January 15, 2021 Notice”), which again provides guidance on reporting instructions and use of funds. Additional guidance or new and amended interpretations of existing guidance on the terms and conditions of such payments may result in changes in the Company’s estimate of amounts for which the terms and conditions are reasonably assured of being met, and any such changes may be material. Additionally, any such changes may result in derecognition of amounts previously recognized, which may be material. As of September 30, 2021, the Company’s estimate of the amount for which it is reasonably assured of meeting the underlying terms and conditions was updated based on, among other things, the September 19, 2020 Notice, the October 22, 2020 Notice, the January 15, 2021 Notice and the Company’s results of operations during 2020 and the nine months ended September 30, 2021. The Company believes that it was appropriate to recognize as income $ 8.0 million of the HHS relief funds in 2020 and $ 4.4 Going Concern Under ASU 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40) (“ASC 205-40”), the Company has the responsibility to evaluate whether conditions and/or events raise substantial doubt about its ability to meet its future financial obligations as they become due within one year after the date that the financial statements are issued. As required by ASC 205-40, this evaluation shall initially not take into consideration the potential mitigating effects of plans that have not been fully implemented as of the date the financial statements are issued. Management has assessed the Company’s ability to continue as a going concern in accordance with the requirements of ASC 205-40. As reflected in the unaudited condensed consolidated financial statements, the Company had a working capital deficit and a stockholders’ deficit of $ 54.3 37.5 2.4 4.2 10.2 11.3 5.7 13.5 The Company’s unaudited condensed consolidated financial statements are prepared assuming the Company can continue as a going concern, which contemplates continuity of operations through realization of assets, and the settling of liabilities in the normal course of business. As more fully discussed in Note 14, on June 25, 2021, the Company sold HTS and AMSG to InnovaQor and the Company received InnovaQor’s Series B Preferred Stock valued at $ 9.1 2.2 There can be no assurance that the Company will be able to achieve its business plan, which is to acquire and operate clusters of rural hospitals and related healthcare service providers, raise any additional capital or secure the additional financing necessary to implement its current operating plan. The ability of the Company to continue as a going concern is dependent upon its ability to raise adequate capital to fund its operations and repay its outstanding debt and other past due obligations, fully align its operating costs, increase its revenues, and eventually regain profitable operations. The unaudited condensed consolidated financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Loss Per Share

Loss Per Share	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Loss Per Share	Note 3 – Loss Per Share Basic loss per share is computed by dividing the loss available to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Basic loss per share excludes potential dilution of securities or other contracts to issue shares of common stock. Diluted loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the income of the Company. For each of the three and nine months ended September 30, 2021 and 2020, basic loss per share is the same as diluted loss per share. The following table sets forth the computation of the Company’s basic and diluted net loss per share available to common stockholders during the three and nine months ended September 30, 2021 and 2020 (unaudited): Schedule of Earnings Per Share Available to Common stockholders 2021 2020 2021 2020 Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator Net income (loss) from continuing operations $ 785,565 $ (6,025,885 ) $ (4,371,860 ) $ (9,697,922 ) Deemed dividends (259,530,999 ) (63,544,950 ) (409,142,478 ) (66,695,318 ) Net loss available to common stockholders, continuing operations (258,745,434 ) (69,570,835 ) (413,514,338 ) (76,393,240 ) Net income (loss) from discontinued operations 545,399 (166,180 ) 10,880,148 (164,293 ) Net loss available to common stockholders $ (258,200,035 ) $ (69,737,015 ) $ (402,634,190 ) $ (76,557,533 ) Denominator Basic and diluted weighted average shares of common stock outstanding 438,998,913 1,284 150,459,817 1,086 Loss per share available to common stockholders- basic and diluted: Continuing operations $ (0.59 ) $ (54,182.89 ) $ (2.75 ) $ (70,343.68 ) Discontinued operations $ 0.00 $ (129.42 ) $ 0.07 $ (151.28 ) Total basic and diluted $ (0.59 ) $ (54,312.31 ) $ (2.68 ) $ (70,494.96 ) Diluted loss per share excludes all dilutive potential shares if their effect is anti-dilutive. As of September 30, 2021 and 2020, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 September 30, 2021 2020 Warrants 182,663,835,039 335,461 Convertible preferred stock 89,770,798,934 313,808 Convertible debentures 9,664,944,444 51,133 Stock options 26 26 Dilutive potential shares 282,099,578,443 700,428 The terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to floors in certain cases) in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. In addition, many of these equity-based securities contain exercise or conversion prices that vary based upon the price of the Company’s common stock on the date of exercise/conversion (see Notes 7, 11 and 12). These provisions have resulted in significant dilution of the Company’s common stock. As a result of these down round provisions, the potential common stock equivalents, including outstanding common stock, totaled 476.2

Accounts Receivable and Income

Accounts Receivable and Income Tax Refunds Receivable	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
Accounts Receivable and Income Tax Refunds Receivable	Note 4 – Accounts Receivable and Income Tax Refunds Receivable Accounts receivable at September 30, 2021 (unaudited) and December 31, 2020 consisted of the following: Schedule of Accounts Receivable September 30, December 31, September 30, December 31, 2021 2020 Accounts receivable $ 9,626,490 $ 16,922,576 Less: Allowance for contractual obligations (6,788,342 ) (13,185,843 ) Allowance for doubtful accounts (992,330 ) (1,513,827 ) Accounts receivable owed under settlement/sales agreements (847,059 ) (1,723,452 ) Accounts receivable, net $ 998,759 $ 499,454 The allowances reflected in the table above decreased as a percentage of accounts receivable to 80.8 86.9 Estimated implicit price concessions deducted from revenues for the three months ended September 30, 2021 and 2020 were $ 1.9 million and $ 2.2 million, respectively, and for the nine months ended September 30, 2021 and 2020 were $ 6.2 million and $ 6.2 million, respectively. The allowance for doubtful accounts deducted from accounts receivable was $ 1.0 million at September 30, 2021 compared to $ 1.5 million at December 31, 2020, a decrease of $ 0.5 million. The decrease was due to lower implicit price concessions in the three months ended September 30, 2021 and to write offs of past due accounts receivable. The Company’s policy is to write off accounts receivable balances against the allowance for implicit price concessions once an accounts receivable ages past a specified number of days. Accounts Receivable Sales Agreements During the year ended December 31, 2020, the Company entered into six accounts receivable sales agreements under which the Company sold an aggregate of $ 3.3 2.2 0.1 1.2 1.7 0.9 52,941 0.6 Income Tax Refunds Receivable As of September 30, 2021 and December 31, 2020, the Company had $ 1.1 1.4 1.1 0.3 0.3 No 0.3

Accrued Expenses

Accrued Expenses	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Accrued Expenses	Note 5 – Accrued Expenses Accrued expenses at September 30, 2021 (unaudited) and December 31, 2020 consisted of the following: Schedule of Accrued Expenses September 30, December 31, 2021 2020 Accrued payroll and related liabilities $ 9,152,027 $ 8,263,940 HHS Provider Relief Funds (See Note 2) - 4,400,000 Accrued interest 5,989,653 4,728,942 Accrued legal 1,097,318 1,097,318 Other accrued expenses 1,203,166 645,369 Accrued expenses $ 17,442,164 $ 19,135,569 Accrued payroll and related liabilities at September 30, 2021 and December 31, 2020 included approximately $ 2.7 2.5 million, respectively, for penalties associated with approximately $ 5.0 4.4 million of accrued past due payroll taxes as of September 30, 2021 and December 31, 2020, respectively.

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Notes Payable	Note 6 – Notes Payable The Company and its subsidiaries are party to a number of loans with third parties and related parties. At September 30, 2021 (unaudited) and December 31, 2020, notes payable consisted of the following: Schedule of Notes Payable Notes Payable – Third Parties September 30, December 31, Loan payable to TCA Global Master Fund, L.P. (“TCA”) in the original principal amount of $ 3 16 Payable in various installments through May 4, 2022 (balance at September 30, 2021 as per settlement agreement – See Note 13) $ 500,000 $ 1,741,893 Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $ 500,000 6 Principal and interest payments due annually from July 12, 2015 through July 12, 2017 291,557 297,068 Note payable to Anthony O’Killough dated September 27, 2019 in the original principal amount of $ 1.9 0.3 0.1 Payment due in installments through November 2020 1,450,000 1,450,000 Notes payable under the PPP loans issued on April 20, 2020 through May 1, 2020 bearing interest at a rate of 1 principal and interest payments are due monthly beginning sixteen months from the date of issuance and the notes mature 40 months from the date of issuance. 1,358,923 2,385,921 Installment promissory note dated January 29, 2020, less original issue discount of $ 0.1 22,500 34,000 - 108,350 Notes payable dated January 31, 2021 and February 16, 2021 due six months from the date of issuance. The notes bear interest at 10 100 245,000 - Notes payable to Western Healthcare, LLC dated August 10, 2021, in the aggregate principal amount of $ 2.4 18 0.2 2,152,961 - Warrant pre-payment promissory notes dated February 25, 2021, April 9, 2021, April 16, 2021 and April 22, 2021, non-interest bearing, $ 1,100,000 100,000 payable 12 months from the date of issuance 1,052,837 - Note payable 7,051,278 5,983,232 Less current portion (7,051,278 ) (4,786,976 ) Notes payable - third parties, net of current portion $ - $ 1,196,256 The Company did not make the required monthly principal and interest payments due under the TCA Debenture for the period from October 2016 through March 2017. On September 19, 2017, the Company entered into a new agreement with TCA, which extended the repayment schedule through December 31, 2017. In May 2020, the SEC appointed a Receiver to close down the TCA Global Master Fund, L.P. The amount recorded by the Company as being owed to TCA as of December 31, 2020 was based on TCA’s application of prior payments made by the Company. The Company and TCA entered into a settlement agreement dated effective as of September 30, 2021, under which the Company agreed to pay TCA a total of $ 500,000 200,000 300,000 50,000 2.2 The Company did not make the second annual principal payment under the Tegal Notes that was due on July 12, 2016. On November 3, 2016, the Company received a default notice from the holders of the Tegal Notes demanding immediate repayment of the outstanding principal at that time of $ 341,612 43,000 50,055 On September 27, 2019, the Company issued a promissory note payable to Anthony O’Killough in the principal amount of $ 1.9 1.5 0.3 0.1 1.0 November 8, 2019 0.9 December 26, 2019 2.2 2.2 450,000 2.2 1.5 0.7 As of April 20, 2020 and through May 1, 2020, the Company and its subsidiaries received PPP loan proceeds in the form of promissory notes (the “PPP Notes”) in the aggregate amount of approximately $ 2.4 million. The PPP Notes and accrued interest are forgivable as long as the borrower uses the loan proceeds for eligible purposes, including payroll, benefits, rent and utilities, and maintains its payroll levels. The amount of loan forgiveness will be reduced if the borrower terminates employees or reduces salaries. No collateral or guarantees were provided in connection with the PPP Notes. The unforgiven portion of the PPP Notes is payable over two years at an interest rate of 1.0 % per annum, with a deferral of payments for the first sixteen months. Beginning sixteen months from the dates of issuance, the Company is required (if not forgiven) to make monthly payments of principal and interest to the lenders. As of September 30, 2021, $ 1.0 million of the principal balance of the PPP Notes has been forgiven and approximately $ 15,000 of accrued interest has been reversed. On November 3, 2021, an additional $ 0.8 million of principal balance was forgiven. On January 29, 2020, the Company entered into a secured installment promissory note (the “Ponte Note”) in the principal amount of $ 1.2 22,500 34,000 due on or before February 5, 2020 through on or before October 21, 2020, the maturity date. 0.1 10 9,850 125,000 On August 10, 2021, the Company entered into two notes payable with Western Healthcare, LLC in the aggregate principal amount of $ 2.4 million. The notes were issued under the terms of a settlement agreement related to professional medical staffing services agreements that the Company had previously entered into for medical staffing services. The notes bear interest at a rate of 18 % per annum and are due no later than August 30, 2022. The Company paid $ 0.2 million to the note holders upon issuance of the notes. Monthly installments aggregating $ 0.2 million are due beginning August 31, 2021. On each of February 25, 2021, April 9, 2021, April 16, 2021 and April 22, 2021, the Company entered into agreements with certain institutional investors for warrant prepayment promissory notes with an aggregate principal amount of $ 1.1 million. The Company received proceeds of $ 1.0 million from the investors and, accordingly, it recorded a total of $ 0.1 million in original issue discount of which $ 25,205 and $ 52,836 was amortized in the three and nine months ended September 30, 2021, respectively. The notes did not bear interest but an interest rate of 18 % would be applied in the event of default that resulted in their acceleration. On November 7, 2021, these notes were exchanged for the Company’s Series P Convertible Redeemable Preferred Stock (the “Series P Preferred Stock”) as more fully discussed in Note 16. Note Payable – Related Party Schedule of Notes Payable - Related Parties September 30, December 31, (unaudited) Note payable to Christopher Diamantis due on demand and bearing interest at 10 $ 2,627,000 $ 2,097,000 Total note payable, related party 2,627,000 2,097,000 Less current portion of note payable, related party (2,627,000 ) (2,097,000 ) Total note payable, related party, net of current portion $ - $ - During the nine months ended September 30, 2021 and 2020, Mr. Christopher Diamantis, a former member of our Board of Directors, loaned the Company $ 0.9 4.6 0.4 4.2 18.8 During the three months ended September 30, 2021 and 2020, the Company accrued interest of $ 0 55,000 0.1 0.5 0.3 0.2 10

Debentures

Debentures	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Debentures	Note 7 – Debentures The carrying amount of all outstanding debentures as of September 30, 2021 and December 31, 2020 is as follows: Schedule of Debentures September 30, 2021 December 31, 2020 (unaudited) Debentures $ 12,690,539 $ 12,690,539 Less current portion (12,690,539 ) (12,690,539 ) Debentures, net of current portion $ - $ - Payment of all outstanding debentures totaling $ 12.7 18 The Company accrued interest expense on outstanding debentures during the three months ended September 30, 2021 and 2020 of $ 0.6 1.5 1.7 5.4 Certain of the debentures are convertible into shares of the Company’s common stock. On September 30, 2021, $ 2.6 million of principal amount of outstanding debentures were convertible into 9.6 billion shares of the Company’s common stock at a price of $ 0.00027 per share and $ 5.6 million of outstanding debentures were convertible on that date into 108.5 million shares of the Company’s common stock at a conversion price of $ 0.052 . The remaining outstanding debentures of $ 4.5 million are non-convertible. See Notes 3 and 11 for a discussion of the dilutive effect of the outstanding convertible debentures and warrants as of September 30, 2021 and Note 16 for the dilutive effect of outstanding convertible debentures and warrants as of November 10, 2021. See Note 11 for a discussion of the exchange of certain debentures for shares of the Company’s Series N Preferred Stock on August 31, 2020 and Note 16 for a discussion of the exchange of certain debentures for shares of the Company’s Series P Preferred Stock.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2021
Related Party Transactions [Abstract]
Related Party Transactions	Note 8 – Related Party Transactions Alcimede LLC Alcimede LLC (“Alcimede”) billed $ 0.1 0.1 0.3 0.3 InnovaQor In addition to the investment in InnovaQor’s Series B Preferred Stock (see Notes 1 and 14), at September 30, 2021, the Company had a receivable from related party resulting from working capital advances to InnovaQor of approximately $ 0.2 51,229 The terms of the foregoing transactions and the transactions discussed in Notes 1, 6, 11 and 14 are not necessarily indicative of those that would have been agreed to with unrelated parties for similar transactions.

Finance and Operating Lease Obl

Finance and Operating Lease Obligations	9 Months Ended
	Sep. 30, 2021
Finance And Operating Lease Obligations
Finance and Operating Lease Obligations	Note 9 – Finance and Operating Lease Obligations We lease property and equipment under finance and operating leases. For leases with terms greater than 12 months, we record the related right-of-use assets and right-of-use obligations at the present value of lease payments over the term. We do not separate lease and non-lease components of contracts. Generally, we use our most recent agreed upon borrowing interest rate at lease commencement as our interest rate, as most of our operating leases do not provide a readily determinable implicit interest rate. The following table presents our lease-related assets and liabilities at September 30, 2021 (unaudited) and December 31, 2020: Schedule of Lease-related Assets and Liabilities Balance Sheet Classification September 30, 2021 December 31, 2020 Assets: Operating leases Right-of-use operating lease assets $ 877,412 $ 1,000,272 Finance leases Property and equipment, net 220,461 249,985 Total lease assets $ 1,097,873 $ 1,250,257 Liabilities: Current: Operating leases Right-of-use operating lease obligations $ 237,026 $ 172,952 Finance leases Current liabilities 220,461 249,985 Noncurrent: Operating leases Right-of-use operating lease obligations 640,386 827,320 Total lease liabilities $ 1,097,873 $ 1,250,257 Weighted-average remaining term: Operating leases 3.50 4.17 Finance leases 0 years 0 years Weighted-average discount rate: Operating leases 13.0 % 13.0 % Finance leases 4.9 % 4.9 % The following table presents certain information related to lease expense for finance and operating leases for the three months and nine months ended September 30, 2021 and 2020: Schedule of Information Related to Lease Expense for Finance and Operating Leases Three Months Ended September 30, 2021 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Finance lease expense: Depreciation/amortization of leased assets $ - $ - $ - $ 26,349 Interest on lease liabilities - - - 9,455 Operating leases: Short-term lease expense (1) 44,342 49,196 151,025 219,138 Total lease expense $ 44,342 $ 49,196 $ 151,025 $ 254,942 (1) Expenses are included in general and administrative expenses in the consolidated statements of operations. Other Information The following table presents supplemental cash flow information for the nine months ended September 30, 2021 and 2020: Schedule of Supplemental Cash Flow Information Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 168,923 $ 98,374 Operating cash flows for finance leases - 9,455 Financing cash flows for finance lease payments 29,524 200,709 Aggregate future minimum lease payments under right-of-use operating and finance leases are as follows: Schedule of Future Minimum Rentals Under Right-to-use Operating and Finance Leases Right-of-Use Operating Leases Finance Leases Twelve months ended September 30, 2022 $ 337,357 $ 224,252 Twelve months ended September 30, 2023 307,082 - Twelve months ended September 30, 2024 217,839 - Twelve months ended September 30, 2025 223,795 - Twelve months ended September 30, 2026 18,650 - Thereafter - - Total 1,104,723 224,252 Less interest - - Present value of minimum lease payments $ 1,104,723 $ 224,252 Less current portion of lease obligations (227,311 ) (3,791 ) Lease obligations, net of current portion $ 877,412 $ 220,461 As of September 30, 2021, the Company was in default under its finance lease obligation, therefore, the aggregate future minimum lease payments and accrued interest under this finance lease totaling approximately $ 0.2

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 10 – Fair Value Measurements Fair Value Measurements We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk. We apply the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs that are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The estimated fair value of financial instruments was determined by the Company using available market information and valuation methodologies considered to be appropriate. At September 30, 2021 and December 31, 2020, the carrying value of the Company’s accounts receivable, accounts payable and accrued expenses approximated their fair values due to their short-term nature. The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2021 and December 31, 2020: Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis Level 1 Level 2 Level 3 Total (unaudited) As of December 31, 2020: InnovaQor Series B Preferred Stock $ - $ - $ - $ - Embedded conversion option of debenture - $ - $ 455,336 $ 455,336 Total $ - $ - $ 455,336 $ 455,336 As of September 30, 2021: InnovaQor Series B Preferred Stock $ - $ - $ 9,016,072 $ 9,016,072 Embedded conversion option of debenture - - 455,336 455,336 Total $ - $ - $ 9,471,408 $ 9,471,408 The fair value of the InnovaQor Series B Preferred Stock of $9.1 million as of September 30, 2021 is more fully discussed in Note 14. The Company utilized the following method to value its derivative liability as of September 30, 2021 and December 31, 2020 for an embedded conversion option related to an outstanding convertible debenture valued at $ 455,336 85 no no During the three and nine months ended September 30, 2021 and 2020, the conversions of preferred stock triggered a further reduction in the exercise prices of debentures and warrants containing ratchet features that had not already ratcheted down to their floor. In accordance with U.S. GAAP, the incremental fair value of the debentures and warrants, as a result of the decreases in the conversion/exercise prices, was measured using Black Scholes. The following assumptions were utilized in the Black Scholes valuation models for the three months ended September 30, 2021: risk free rates ranging from 0.04 % to 0.55 %, volatility ranging from 25.0 % to 574.0 % and terms ranging from one day to three years . The following assumptions were utilized in the Black Scholes valuation models for the nine months ended September 30, 2021: risk free rates ranging from 0.04 % to 0.55 %, volatility ranging from 25.0 % to 574.0 % and terms ranging from one day to three years . The incremental fair value of $ 259.2 million $ 408.5 million was recorded as deemed dividends for the three and nine months ended September 30, 2021, respectively. The following assumptions were utilized in the Black Scholes valuation models for the three and nine months ended September 30, 2020: risk free rates ranging from 0.09 % to 0.12 %, volatility ranging from 134.3 % to 208.2 % and weighted average lives ranging from .25 to 1.49 years. The incremental value of $ 59.8 million was recorded as deemed dividends in both the three and nine months ended September 30, 2020, respectively. In addition, deemed dividends of $0.3 million were recorded in both the three and nine months ended September 30, 2021 as a result of the issuance of warrants to acquire 47.5 million shares of the Company’s common stock and deemed dividends of $0.3 million were recorded in both the three and nine months ended September 2021 as a result of the extension of warrants. These deemed dividends are more fully discussed in Note 11. Deemed dividends of $3.2 million were recorded in the nine months ended September 30, 2020 as a result of the issuance of the Series M Preferred Stock as more fully discussed in Note 11 and deemed dividends of $3.7 million were recorded in the three and nine months ended September 30, 2020 as a result of the issuance of our Series N Preferred Stock as more fully discussed in Note 11. Deemed dividends are also discussed in Notes 1 and 3.

Stockholders_ Deficit

Stockholders’ Deficit	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Stockholders’ Deficit	Note 11 – Stockholders’ Deficit Authorized Capital As of September 30, 2021, the Company had 10,000,000,000 $0.0001 5,000,000 $0.01 50,000,000,000 Preferred Stock The Company has 5,000,000 shares, par value $0.01 , of preferred stock authorized. As of September 30, 2021, the Company had outstanding shares of preferred stock consisting of 1,750,000 shares of its Series F Convertible Preferred Stock, 10 shares of its Series H Convertible Preferred Stock, 250,000 shares of its Series L Convertible Preferred Stock (the “Series L Preferred Stock”), 20,810 .35 shares of its Series M Preferred Stock, 11,084 shares of its Series N Preferred Stock, and 5,500 shares of its Series O Convertible Redeemable Preferred Stock (the “Series O Preferred Stock”). As of September 30, 2021, the Series F Convertible Preferred Stock is convertible into one share of the Company’s common stock and the Series H Convertible Preferred Stock is convertible into 37 million shares of the Company’s common stock. The Series L Preferred Stock, the Series M Preferred Stock, the Series N Preferred Stock and the Series O Preferred Stock are more fully described below. In addition, on November 7, 2021, the Company issued its Series P Preferred Stock, which is more fully described in Note 16. Series L Preferred Stock On May 4, 2020, the Company filed a Certificate of Designation with the Secretary of State of the State of Delaware to authorize the issuance of up to 250,000 250,000 250,000 Series M Preferred Stock The Company’s Board of Directors has designated 30,000 5,000,000 $1,000 $18.8 22,000 $0.01 $3.2 $18.8 $22.0 On August 27, 2021, the Company entered into an exchange agreement with Mr. Diamantis. Pursuant to the exchange agreement, Mr. Diamantis exchanged 570 95,000,000 47.5 $.007 three-year 1.2 $0.00027 $0.3 0.41% 364 three years Each share of the Series M Preferred Stock is convertible into shares of the Company’s common stock at a conversion price equal to 90% of the average closing price of the Company’s common stock on the ten trading days immediately prior to the conversion date but in any event not less than the par value of the Company’s common stock. During the nine months ended September 30, 2021, Mr. Diamantis converted a total of 610.65 shares of his Series M Preferred Stock with a stated value of $0.6 million into 450,000 shares of the Company’s common stock and, as discussed above, he exchanged 570 shares of his Series M Preferred Stock, with a stated value of $0.6 million, into 95,000,000 shares of the Company’s common stock. On August 13, 2020, Mr. Diamantis entered into a Voting Agreement and Irrevocable Proxy with the Company, Mr. Lagan and Alcimede (of which Mr. Lagan is the sole manager) pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan to vote the Series M Preferred Stock held by Mr. Diamantis, Mr. Diamantis has retained all other rights under the Series M Preferred Stock. Series N Preferred Stock On August 31, 2020, the Company and its debenture holders exchanged, under the terms of the Exchange, Redemption and Forbearance Agreements (the “Exchange and Redemption Agreements”), certain outstanding debentures and all of the outstanding shares of the Company’s Series I-1 Convertible Preferred Stock (the “Series I-1 Preferred Stock”) and Series I-2 Convertible Preferred Stock (the “Series I-2 Preferred Stock”) for 30,435,52 shares of the Company’s Series N Preferred Stock. The terms of the Series N Preferred Stock were set forth in the Company’s Current Report on Form 8-K filed with the SEC on September 1, 2020. During the three and nine months ended September 30, 2020, as a result of the Exchange and Redemption Agreements, the Company recorded: (i) a $ 0.4 million gain on the extinguishment of debt, which included the potential exchange premium of $ 1.65 million, and a $ 0.3 million fair value adjustment to the debenture principal, partially offset by the reduction in interest expense of $ 2.3 million; and (ii) deemed dividends of $ 3.7 million as a result of the exchange of the debentures and Series I-1 Preferred Stock and Series I-2 Preferred Stock for shares of the Series N Preferred Stock. During the nine months ended September 30, 2021, the holders converted 18,350.1 shares of their Series N Preferred Stock, with a stated value of $ 18.4 million, into 4.7 billion shares of the Company’s common stock. During the nine months ended September 30, 2020, the holders converted 131 shares of their Series N Preferred Stock, with a stated value of $ 0.1 million, into 589 shares of the Company’s common stock. Series O Preferred Stock On May 10, 2021, the Company closed an offering of shares of its newly-authorized Series O Preferred Stock. The offering was pursuant to the terms of the Securities Purchase Agreement, dated as of May 10, 2021 (the “Purchase Agreement”), between the Company and certain existing institutional investors of the Company. The Purchase Agreement provided for the issuance of up to 4,400 shares of Series O Preferred Stock at four closings of 1,100 shares each. The four closings occurred on May 10, 2021, May 18, 2021, July 12, 2021 and August 10, 2021. The Company entered into a second Securities Purchase Agreement (the “Second Purchase Agreement”), dated as of September 7, 2021, between the Company and the existing institutional investors of the Company. The Second Purchase Agreement provided for the issuance of up to 1,100 shares of the Series O Preferred Stock at two closings of 550 shares each. The two closings under the Second Purchase Agreement occurred on September 7, 2021 and September 30, 2021. As a result, as of September 30, 3021, the Company has issued 5,500 $5.0 $2.5 $2.5 On October 28, 2021, the Company entered into the Securities Purchase Agreement, dated as of October 28, 2021 (the “October 28 Agreement”), among the Company and certain existing institutional investors of the Company. The October 28 Agreement provides for the issuance of up to 4,400 2,200 The Series O Preferred Stock, which has been issued for cash, does not contain mandatory redemption or other features that would require it to be presented on the balance sheet outside of equity and, therefore, it qualifies for equity accounting treatment. As a result of the equity accounting treatment, fair value accounting is not required in connection with the issuances of the stock and no gains, losses, derivative liabilities or deemed dividends have been recorded in connection with the issuances of the stock. The terms of the Series O Preferred Stock were set forth in the Company’s Current Report on Form 8-K filed with the SEC on May 11, 2021, in particular: General 10,000 5,000,000 $1,000 Voting Rights Dividends 10% provided however Rank Conversion The conversion price is equal to 90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date. Holders of the Series O Preferred Stock are prohibited from converting Series O Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after notice to the Company. Liquidation Preference Redemption Common Stock The Company had 4,777,350,000 39,648 450,000 619.65 95,000,000 18,355.5 313 236.3 589 131 The Company has outstanding options, warrants, convertible preferred stock and convertible debentures. Exercise of the options and warrants, and conversions of the convertible preferred stock and debentures could result in substantial dilution of the Company’s common stock and a decline in the market price of the common stock. In addition, the terms of certain of the warrants, convertible preferred stock and convertible debentures issued by the Company provide for reductions in the per share exercise prices of the warrants and the per share conversion prices of the debentures and preferred stock (if applicable and subject to a floor in certain cases), in the event that the Company issues common stock or common stock equivalents (as that term is defined in the agreements) at an effective exercise/conversion price that is less than the then exercise/conversion prices of the outstanding warrants, preferred stock or debentures, as the case may be. These provisions, as well as the issuances of debentures and preferred stock with conversion prices that vary based upon the price of our common stock on the date of conversion, have resulted in significant dilution of the Company’s common stock and have given rise to reverse splits of its common stock, including the Reverse Stock Splits, which are more fully discussed in Note 1. See Note 16 for a discussion of the number of shares of the Company’s common stock and common stock equivalents outstanding as of November 10, 2021. On August 13, 2020, Mr. Diamantis entered into the Voting Agreement with the Company, Mr. Lagan and Alcimede (of which Mr. Lagan is the sole manager) pursuant to which Mr. Diamantis granted an irrevocable proxy to Mr. Lagan to vote the Series M Preferred Stock held by Mr. Diamantis. Mr. Diamantis has retained all other rights under the Series M Preferred Stock. Regardless of the number of shares of Series M Preferred Stock outstanding and so long as at least one share of Series M Preferred Stock is outstanding, the outstanding shares of Series M Preferred Stock shall have the number of votes, in the aggregate, equal to 51% of all votes entitled to be voted at any meeting of stockholders or action by written consent. This means that the holders of Series M Preferred Stock have sufficient votes, by themselves, to approve or defeat any proposal voted on by the Company’s stockholders, unless there is a supermajority required under applicable law or by agreement. As a result of the Voting Agreement, as of the date of filing this report, the Company believes that it has the ability to ensure that it has and or can obtain sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding. Effective November 5, 2021, the Company increased its authorized shares of common stock to 50,000,000,000 Stock Options The Company maintained and sponsored the Tegal Corporation 2007 Incentive Award Equity Plan (the “2007 Equity Plan”). Tegal Corporation is the prior name of the Company. The 2007 Equity Plan, as amended, provided for the issuance of stock options and other equity awards to the Company’s officers, directors, employees and consultants. The 2007 Equity Plan terminated pursuant to its terms in September 2017. As of September 30, 2021, 26 $2,992,125 4.62 Warrants The Company, as part of various debt and equity financing transactions, has issued warrants to purchase shares of the Company’s common stock exercisable into a total of 182.7 billion shares at September 30, 2021. During the nine months ended September 30, 2021, as a result of the anti-dilution provisions of outstanding warrants, the exercise prices of certain warrants decreased and they became exercisable into an additional 182.7 billion shares of the Company’s common stock. Certain of these warrants were issued in connection with the issuances of the debentures. Debentures are more fully discussed in Note 7. Included in the warrants outstanding at September 30, 2021, were warrants issued in connection with the debentures issued in March 2017. The Company issued these warrants to purchase shares of the Company’s common stock to several accredited investors (the “March Warrants”). At September 30, 2021, these warrants were exercisable into an aggregate of approximately 177.8 billion shares of the Company’s common stock. The March Warrants were issued to the investors in three tranches, Series A Warrants, Series B Warrants and Series C Warrants. At September 30, 2021, the Series A Warrants were exercisable for 66.5 billion shares of the Company’s common stock. They were exercisable upon issuance and have a term of exercise equal to five years . At September 30, 2021, the Series B Warrants were exercisable for 42.6 billion shares of the Company’s common stock and are exercisable until March 31, 2022. At September 30, 2021, the Series C Warrants were exercisable for 68.7 billion shares of the Company’s common stock and have a term of five years provided such warrants shall only vest if, when and to the extent that the holders exercise the Series B Warrants. On November 7, 2021, the expiration dates of the March Warrants were extended to March 21, 2024 $0.00027 per share, which reflects adjustments pursuant to their terms. The March Warrants are subject to “full ratchet” and other customary anti-dilution protections. During the three and nine months ended September 30, 2021 and 2020, reductions in the exercise prices of the March Warrants have given rise to deemed dividends. Deemed dividends are also discussed below and in Notes 1, 3 and 10. The Company extended certain common stock warrants during the three and nine months ended September 30, 2021, and as a result of the extension, deemed dividends of $ 0.3 0.05% 230 six months The number of shares of common stock issuable under warrants issued and outstanding as well as the exercise prices of the warrants reflected in the table below have been adjusted to reflect the full ratchet and other dilutive and down round provisions pursuant to the warrant agreements. As a result of the full ratchet provisions of the majority of the outstanding warrants (subject to a floor in some cases), subsequent issuances of the Company’s common stock or common stock equivalents at prices below the then current exercise prices of the warrants have resulted in increases in the number of shares issuable pursuant to the warrants and decreases in the exercise prices of the warrants. The following summarizes the information related to the number of shares of common stock issuable under outstanding warrants during the nine months ended September 30, 2021: Schedule of Warrants Activity Number of Shares of Common Stock Issuable for Warrants Weighted average exercise price Balance at December 31, 2020 4,571,165 $ 19.99 Issuance of warrants 47,500,000 0.007 Expiration of warrants (44,078,213 ) (0.3110 ) Increase in number of shares of common stock issuable under warrants during the period as a result of down round provisions 182,655,951,726 - Balance at September 30, 2021 182,663,835,038 $ 0.00043 The 47.5 “Series M Preferred Stock.”

Supplemental Disclosure of Cash

Supplemental Disclosure of Cash Flow Information	9 Months Ended
	Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Supplemental Disclosure of Cash Flow Information	Note 12 – Supplemental Disclosure of Cash Flow Information Schedule of Supplemental Disclosure of Cash Flow Information 2021 2020 Nine Months Ended September 30, 2021 2020 Cash paid for interest $ - $ 64,454 Cash paid for income taxes $ 281,025 $ - Non-cash investing and financing activities: Preferred stock of InnovaQor received from the sale of HTS and AMSG $ 9,117,500 $ - Net liabilities of HTS and AMSG transferred to InnovaQor 2,227,152 - Settlement of liability with InnovaQor preferred stock 60,714 - Issuance of notes payable in settlement of accounts payable and accrued expenses 2,352,961 - Series I-2 Preferred Stock converted into common stock - 277,994 Exchange of Series K Preferred Stock for Series L Preferred Stock - (2,500 ) Issuance of Series L Preferred Stock - 2,500 Issuance of Series M Preferred Stock in exchange for related party loans and accrued interest - 22,000,000 Loans and accrued interest exchanged for Series M Preferred Stock - (18,849,632 ) Deemed dividend from exchange of loans and accrued interest for Series M Preferred Stock - 3,150,368 Series M Preferred Stock converted/exchanged into common stock 1,189,650 - Deemed dividends from issuance of common stock warrants under exchange agreement 341,525 - Issuance of Series N Preferred Stock in exchange for debentures, accrued interest and Series I-1 and Series I-2 Preferred Stock - 30,435,519 Debentures, accrued interest and Series I-1 and Series I-2 Preferred Stock exchanged for Series N Preferred Stock - (19,342,322 ) Series N Preferred Stock converted into common stock 18,355,507 58 Deemed dividends from the issuance of Series N Preferred Stock - 3,720,718 Deemed dividends for trigger of down round provisions 408,509,361 59,824,232 Deemed dividends from extension of common stock warrants 291,592 - Original issue discounts on debt 52,836 108,958

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13 – Commitments and Contingencies Concentration of Credit Risk Credit risk with respect to accounts receivable is generally diversified due to the large number of patients comprising the accounts receivable. The Company has receivable balances with government payers and various insurance carriers. The Company does not require collateral or other security to support customer receivables. However, the Company continually monitors and evaluates its collection procedures to minimize potential credit risks associated with its accounts receivable and establishes an allowance for uncollectible accounts and as a consequence, believes that its accounts receivable credit risk exposure beyond such allowance is not material to the financial statements. A number of proposals for legislation continue to be under discussion which could substantially reduce Medicare and Medicaid reimbursements to hospitals. Depending upon the nature of regulatory action, and the content of legislation, the Company could experience a significant decrease in revenues from Medicare and Medicaid, which could have a material adverse effect on the Company. The Company is unable to predict, however, the extent to which such actions will be taken. The Company maintains its cash balances in high credit quality financial institutions. The Company’s cash balances may, at times, exceed the deposit insurance limits provided by the Federal Deposit Insurance Corporation. Legal Matters From time to time, the Company may be involved in a variety of claims, lawsuits, investigations and proceedings related to contractual disputes, employment matters, regulatory and compliance matters, intellectual property rights and other litigation arising in the ordinary course of business. The Company operates in a highly regulated industry which may inherently lend itself to legal matters. Management is aware that litigation has associated costs and that results of adverse litigation verdicts could have a material effect on the Company’s financial position or results of operations. The Company’s policy is to expense legal fees and expenses incurred in connection with the legal proceedings in the period in which the expense is incurred. Management, in consultation with legal counsel, has addressed known assertions and predicted unasserted claims below. Biohealth Medical Laboratory, Inc. and PB Laboratories, LLC (the “Companies”) filed suit against CIGNA Health in 2015 alleging that CIGNA failed to pay claims for laboratory services the Companies provided to patients pursuant to CIGNA - issued and CIGNA - administered plans. In 2016, the U.S. District Court dismissed part of the Companies’ claims for lack of standing. The Companies appealed that decision to the Eleventh Circuit Court of Appeals, which in late 2017 reversed the District Court’s decision and found that the Companies have standing to raise claims arising out of traditional insurance plans as well as self-funded plans. In July 2019, the Companies and EPIC Reference Labs, Inc. filed suit against CIGNA Health for failure to pay claims for laboratory services provided. Cigna Health, in turn, sued for improper billing practices. The suit remains ongoing but because the Company did not have the financial resources to see the legal action to conclusion it assigned the benefit, if any, from the suit to Christopher Diamantis for his continued financial support to the Company and assumption of all costs to carry the cost to conclusion. In November of 2016, the IRS commenced an audit of the Company’s 2015 Federal tax return. Based upon the audit results, the Company made provisions of approximately $ 1.0 0.9 1.1 0.3 0.3 1.1 0.8 On September 27, 2016, a tax warrant was issued against the Company by the Florida Department of Revenue (the “DOR”) for unpaid 2014 state income taxes in the approximate amount of $ 0.9 0.4 In December of 2016, DeLage Landen Financial Services, Inc. (“DeLage”), filed suit against the Company for failure to make the required payments under an equipment leasing contract that the Company had with DeLage (see Note 9). On January 24, 2017, DeLage received a default judgment against the Company in the approximate amount of $ 1.0 4.97% 0.2 On December 7, 2016, the holders of the Tegal Notes (see Note 6) filed suit against the Company seeking payment for the amounts due under the notes in the aggregate of the principal of $ 341,612 43,000 50,055 The Company, as well as many of its subsidiaries, were defendants in a case filed in Broward County Circuit Court by TCA Global Credit Master Fund, L.P. The plaintiff alleged a breach by Medytox Solutions, Inc. of its obligations under a debenture and claimed damages of approximately $ 2,030,000 plus interest, costs and fees. The Company and the other subsidiaries were sued as alleged guarantors of the debenture. The complaint was filed on August 1, 2018. In May 2020, the SEC appointed a Receiver to close down the TCA Global Master Fund, L.P. The Company and TCA entered into a settlement agreement dated effective as of September 30, 2021, under which the Company agreed to pay TCA $500,000 as full and final settlement of principal and interest, of which $200,000 was paid on November 4, 2021 and the remaining $300,000 is due in six consecutive monthly installments of $50,000 payable on or before the fifth day of each month beginning December 2021. As a result of the settlement, the Company recorded a gain from legal settlement of $2.2 million in the three and nine months ended September 30, 2021. On September 13, 2018, Laboratory Corporation of America sued EPIC Reference Labs, Inc., a subsidiary of the Company, in Palm Beach County Circuit Court for amounts claimed to be owed. The court awarded a judgment against EPIC Reference Labs, Inc. in May 2019 for approximately $ 155,000 In February 2020, Anthony O. Killough sued the Company and Mr. Diamantis, as guarantor, in New York State Supreme Court for the County of New York, for approximately $ 2.0 2,158,168 1.5 0.7 20% In February 2021, a supplier to the Company’s hospitals, Shared Medical Services, Inc., filed suit in Palm Beach County Circuit Court for approximately $ 90,000 100,000 50,000 Following the Company’s decision to suspend operations at Jamestown Regional Medical Center in June 2019 a number of vendors remain unpaid. A number have initiated or threatened legal actions. The Company believes it will come to satisfactory arrangements with these parties as it works toward reopening the hospital. The Company has accrued the amounts that it expects to owe in its financial statements. The Company plans to reopen the hospital upon securing adequate capital to do so. The reopening plans have also been disrupted by the COVID-19 pandemic and the timing of the reopening has been delayed. It is now intended that the re-opening process will be initiated in 2022. Two former employees of Jamestown Regional Medical Center filed suit alleging violations of the federal Worker Adjustment and Retraining Notification Act (“WARN”). The Court entered a default against the Company on August 14, 2019. The parties disagreed to the amount of damages, specifically to whether part-time employees are entitled to WARN act damages. The parties have agreed to a settlement agreement dated May 14, 2021. Pursuant to the terms of this agreement, the Company was required to pay a sum of $ 425,000 In June 2019, CHSPSC, the former owners of Jamestown Regional Medical Center, obtained a judgment against the Company in the amount of $ 592,650 . The Company has recorded $ 130,000 of this judgment as a liability as of September 30, 2021, as management believes that a number of insurance payments were made to CHSPSC after the change of ownership and will likely offset the majority of the claim made by CHSPSC. In August 2019, Morrison Management Specialists, Inc. obtained a judgment against Jamestown Regional Medical Center and the Company in Fentress County, Tennessee in the amount of $ 194,455 In November 2019, Newstat, PLLC obtained a judgment against Big South Fork Medical Center in Knox County, Tennessee in the amount of $ 190,600 On June 30, 2021, the Company entered into a settlement agreement with the Tennessee Bureau of Workers’ Compensation. Per the terms of the settlement agreement, the Company is obligated to pay a total of $ 109,739 32,922 3,201 th In July 2021, WG Fund, Queen Funding and Diesel Funding filed legal actions in New York State Supreme Court for Kings County to recover amounts claimed to be outstanding on accounts receivable sales agreements entered into in 2020. On September 14, 2021, the Company entered into separate stipulation of settlement agreements with the three funding parties under which the Company agreed to repay an aggregate of $ 0.9 52,941

Discontinued Operations

Discontinued Operations	9 Months Ended
	Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Discontinued Operations	Note 14 – Discontinued Operations Sale of HTS and AMSG In 2017, the Company announced plans to spin off or sell its wholly-owned subsidiaries, HTS and AMSG. On June 25, 2021, the Company sold the shares of stock of HTS and AMSG to InnovaQor. HTS and AMSG held Rennova’s software and genetic testing interpretation divisions. In consideration for the shares of HTS and AMSG and the elimination of intercompany debt among the Company and HTS and AMSG, InnovaQor issued the Company 14,950 14,000 950 $1,000 90% 4.99% As a result of the sale, the Company recorded the InnovaQor Series B Preferred Stock as a long-term asset valued at $ 9.1 million at September 30, 2021 and a gain on the sale of HTS and AMSG of $ 0.6 million in the three months ended September 30, 2021, which resulted from the value of the 950 shares of InnovaQor Series B Preferred Stock received as a result of a post-closing adjustment, and a gain on the sale of HTS and AMSG of $ 11.3 million in the nine months ended September 30, 2021, of which $ 9.1 million resulted from the value of the InnovaQor Series B Preferred Stock and $ 2.2 million resulted from the transfer to InnovaQor of the net liabilities of HTS and AMSG. A discussion of the assumptions used in the valuation of the InnovaQor Series B Preferred Stock is presented below. During the three and nine months ended September 30, 2021, 100 shares of InnovaQor Series B Preferred Stock valued at $ 60,714 were used to settle accrued interest that was due under the terms of notes payable dated January 31, 2021 and February 16, 2021. The notes payable are more fully discussed in Note 6. See Note 8 for a discussion of related party transactions between the Company and InnovaQor. EPIC Reference Labs, Inc. During the three months ended September 30, 2020, the Company made a decision to sell its last clinical laboratory, EPIC Reference Labs, Inc., and it made a decision to discontinue several other non-operating subsidiaries, and as a result, EPIC Reference Labs, Inc.’s operations and the other non-operating subsidiaries have been included in discontinued operations for all periods presented. The Company has been unable to find a buyer for EPIC Reference Labs, Inc. and, therefore, it has ceased all efforts to sell the company and closed down its operations. Carrying amounts of major classes of assets and liabilities sold or included as part of discontinued operations in the consolidated balance sheets as of September 30, 2021 and December 31, 2020 consisted of the following: Schedule of Discontinued Operation of Balance Sheet and Operation Statement HTS and AMSG Assets and Liabilities: September 30, 2021 December 31, 2020 (unaudited) Cash $ $ 31,294 Accounts receivable, net - 151,363 Prepaid expenses and other current assets - 1,717 Current assets classified as held for sale $ - $ 184,374 Property and equipment, net $ - $ 685 Deposits - - Right-of-use assets - - Non-current assets classified as held for sale $ - $ 685 Accounts payable and checks issued in excess of bank balance $ - $ 726,220 Accrued expenses - 1,308,283 Current portion of right-of-use operating lease obligation - - Current portion of notes payable - 168,751 Current liabilities classified as held for sale $ - $ 2,203,254 Note payable $ - $ 69,267 Right-of-use operating lease obligation - - Non-current liabilities classified as held for sale $ - $ 69,267 EPIC Reference Labs, Inc. and Other Subsidiaries Assets and Liabilities: September 30, December 31, (unaudited) Cash $ - $ 136 Accounts receivable, net - - Prepaid expenses and other current assets - - Current assets classified as held for sale $ - $ 136 Property and equipment, net $ - $ - Deposits 5,014 100,014 Right-of-use assets - 100,116 Non-current assets classified as held for sale $ 5,014 $ 200,130 Accounts payable and checks in excess of bank balance $ 1,111,557 $ 1,185,158 Accrued expenses 336,410 334,667 Current portion of right-of-use operating lease obligation - 91,166 Current portion of notes payable - - Current liabilities classified as held for sale $ 1,447,967 $ 1,610,991 Note payable $ - $ - Right-of-use operating lease obligation - 8,950 Non-current liabilities classified as held for sale $ - $ 8,950 Consolidated Discontinued Operations Assets and Liabilities: September 30, December 31, (unaudited) Cash $ - $ 31,430 Accounts receivable, net - 151,363 Prepaid expenses and other current assets - 1,717 Current assets classified as held for sale $ - $ 184,510 Property and equipment, net $ - $ 685 Deposits 5,014 100,014 Right-of-use assets - 100,116 Non-current assets classified as held for sale $ 5,014 $ 200,815 Accounts payable and checks issued in excess of bank balance $ 1,111,557 $ 1,911,378 Accrued expenses 336,410 1,642,950 Current portion of right-of-use operating lease obligation - 91,166 Current portion of notes payable - 168,751 Current liabilities classified as held for sale $ 1,447,967 $ 3,814,245 Note payable $ - $ 69,267 Right-of-use operating lease obligation - 8,950 Non-current liabilities classified as held for sale $ - $ 78,217 Major line items constituting income (loss) from discontinued operations in the consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 consisted of the following (unaudited): HTS and AMSG Income (Loss) from Discontinued Operations (unaudited): Three Months Three Months Ended Nine Months Nine Months Revenue from services $ - $ 174,941 $ 216,941 $ 437,119 Cost of services - 390 2,386 11,379 Gross profit - 174,551 214,555 425,740 Operating expenses - (258,710 ) (551,296 ) (509,989 ) Other income (expense) - (9,636 ) (9,577 ) (61,067 ) Gain on sale 576,787 - 11,303,939 - Provision for income taxes - - - - Income (loss) from discontinued operations $ 576,787 $ (93,795 ) $ 10,957,621 $ (145,316 ) The fair value of the InnovaQor Series B Preferred Stock that the Company received as consideration for the sale of $9.1 million was based on a third-party valuation using the Option Price Method (the “OPM”). The OPM treats common and preferred interests as call options on the equity value of the subject company, with exercise prices based on the liquidation preference of the preferred interests and participation thresholds for subordinated classes. The common interest is modeled as a call option that gives its owner the right but not the obligation to buy the enterprise value at a predetermined or exercise price. In the model, the exercise price is based on a comparison with the enterprise value rather than, as in the case of a “regular” call option, a comparison with a per share stock price. Thus, the common interest is considered to be a call option with a claim on the enterprise at an exercise price equal to the remaining value immediately after the preferred interests are liquidated. The Black Scholes model was used to price the call options. The assumptions used were: risk free rate of 0.84%; volatility of 250.0%; and exit period of 5 years. Lastly, a discount rate of 35% was applied due to the lack of marketability of the InnovaQor Series B Preferred Stock and the underlying liquidity of InnovaQor’s common stock. EPIC Reference Labs, Inc. and Other Subsidiaries Income (Loss) from Discontinued Operations (unaudited): Three Months Three Months Ended Nine Months Nine Months Revenue from services $ - $ - $ - $ 441 Cost of services - - - - Gross profit - - - 441 Operating expenses (31,388 ) (41,439 ) (126,243 ) (106,704 ) Other income (expense) - (30,946 ) 48,770 87,286 Gain on sale - - - - Provision for income taxes - - - - Loss from discontinued operations $ (31,388 ) $ (72,385 ) $ (77,473 ) $ (18,977 ) Consolidated Income (Loss) from Discontinued Operations (unaudited): Three Months Three Months Ended Nine Months Nine Months Revenue from services $ - $ 174,941 $ 216,941 $ 437,560 Cost of services - 390 2,386 11,379 Gross profit - 174,551 214,555 426,181 Operating expenses (31,388 ) (300,149 ) (677,539 ) (616,693 ) Other income (expense) - (40,582 ) 39,193 26,219 Gain on sale 576,787 - 11,303,939 - Provision for income taxes - - - - Income (loss) from discontinued operations $ 545,399 $ (166,180 ) $ 10,880,148 $ (164,293 )

Recent Accounting Pronouncement

Recent Accounting Pronouncements	9 Months Ended
	Sep. 30, 2021
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Pronouncements	Note 15 – Recent Accounting Pronouncements In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40). In May 2021, the FASB issued ASU 2021-04, Earnings Per Share (Topic 260), Debt—Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options. Other recent accounting standards issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the SEC did not or are not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 16 – Subsequent Events PPP Notes On November 3, 2021, $ 0.8 Shareholder Proposals Effective November 5, 2021 On November 5, 2021, the Company filed an Amendment to its Articles of Incorporation, as amended (the “Amendment”), with the Secretary of State of Delaware to make effective the following proposals, which had previously been approved by the Company’s Board of Directors and stockholders: Proposal 1 10,000,000,000 50,000,000,000 Proposal 2 As a result of the Voting Agreement discussed in Note 11 and the two proposals above that became effective on November 5, 2021, as of the date of filing this report, the Company believes that it has the ability to ensure that it has and or can obtain sufficient authorized shares of its common stock to cover all potentially dilutive common shares outstanding. Issuances of Preferred Stock On October 28, 2021, the Company entered into the October 28 Agreement among the Company and certain existing institutional investors of the Company. The October 28 Agreement provides for the issuance of up to 4,400 shares of the Company’s Series O Preferred Stock at two closings of 2,200 shares each. The first closing occurred on October 28, 2021 in which the Company received $ 2.0 million. The second closing is expected to occur on or before December 1, 2021. The subsequent closing depends upon the Company’s satisfaction of certain conditions. If the second closing occurs, the Company will receive proceeds of $ 2.0 million. Debt Exchange and Amendment Agreements On November 7, 2021, the Company entered into Exchange and Amendment Agreements (the “November 2021 Exchange Agreements”) with certain institutional investors in the Company. In the November 2021 Exchange Agreements, the investors agreed to reduce their holdings of $ 1.1 million stated amount of outstanding warrant promissory notes payable and $ 4.5 million of outstanding non-convertible debentures, plus accrued interest thereon of approximately $ 1.4 million, by exchanging the indebtedness and accrued interest for 8,545 shares of the Company’s Series P Preferred Stock. The warrant promissory notes payable and the debentures are more fully discussed in Notes 6 and 7, respectively. After the exchange, the investors continue to own approximately $ 8.2 million of the outstanding debentures, plus the associated accrued interest of approximately $ 3.3 million. In addition, pursuant to the November 2021 Exchange Agreements, the expiration dates of the March Warrants that were issued by the Company to the investors in March 2017, as more fully described in Note 11, were extended from varying dates in March 2022 to March 21, 2024. The terms of the Series P Preferred Stock are set forth in the Company’s Current Report on Form 8-K filed with the SEC on November 8, 2021, in particular: General 30,000 5,000,000 1,000 Voting Rights Dividends 10 provided however Rank Conversion The conversion price is equal to 90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date. Holders of the Series P Preferred Stock are prohibited from converting Series P Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after notice to the Company. Liquidation Preference Redemption Issuances of Common Stock Subsequent to September 30, 2021 and through November 10, 2021, the Company issued 8.7 2,495.84 2.5 Potential Common Stock as of November 10, 2021 The following table presents the potential dilutive effect of our various equity-linked instruments as of November 10, 2021: Schedule of Dilutive Effect of Various Potential Common Shares November 10, Shares of common stock outstanding 13,491,000,000 Dilutive potential shares: Convertible preferred stock 174,319,763,738 Warrants 273,995,752,554 Convertible debt 14,443,166,667 Stock options 26 Total dilutive potential shares of common stock, including outstanding common stock 476,249,682,985

Organization and Summary of S_2

Organization and Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
Description of Business	Description of Business Rennova Health, Inc. (“Rennova”, together with its subsidiaries, the “Company”, “we”, “us” or “our”) is a provider of health care services. The Company owns one operating hospital in Oneida, Tennessee, a hospital located in Jamestown, Tennessee that it plans to reopen and operate, a physician’s office in Jamestown, Tennessee that it plans to reopen and a rural clinic in Kentucky. The Company’s operations consist of one business segment.
Basis of Presentation	Basis of Presentation The accompanying unaudited condensed consolidated financial statements were prepared using generally accepted accounting principles for interim financial information and the instructions to Form 10-Q and Regulation S-X. Accordingly, these financial statements do not include all information or notes required by generally accepted accounting principles for annual financial statements and should be read in conjunction with the consolidated financial statements as filed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. In the opinion of management, the unaudited condensed consolidated financial statements included herein contain all adjustments necessary to present fairly the Company’s consolidated financial position as of September 30, 2021, the results of its operations and changes in stockholders’ deficit for the three and nine months ended September 30, 2021 and 2020 and its cash flows for the nine months ended September 30, 2021 and 2020. Such adjustments are of a normal recurring nature. The results of operations for the nine months ended September 30, 2021 may not be indicative of results for the entire year ending December 31, 2021.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”), include the accounts of Rennova and its wholly-owned subsidiaries. All intercompany transactions and balances have been eliminated in the consolidation.
Comprehensive Income (Loss)	Comprehensive Income (Loss) During the three and nine months ended September 30, 2021 and 2020, comprehensive income (loss) was equal to the net income (loss) amounts presented in the accompanying unaudited condensed consolidated statements of operations.
Reclassifications	Reclassifications Certain items in the financial statements for the three and nine months ended September 30, 2020 were reclassified for comparison purposes.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of net revenues and expenses during the reporting period. Significant estimates and assumptions include the estimates of fair values of assets acquired and liabilities assumed in business combinations, including hospital acquisitions, the fair values of consideration received from the sale of subsidiaries, reserves and write-downs related to receivables and inventories, the recoverability of long-lived assets, the valuation allowance relating to the Company’s deferred tax assets, the valuation of equity and derivative instruments, deemed dividends and debt discounts, among others. Actual results could differ from those estimates and would impact future results of operations and cash flows.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid temporary cash investments with an original maturity of three months or less to be cash equivalents.
Reverse Stock Splits	Reverse Stock Splits On July 22, 2020, the Company’s Board of Directors approved an amendment to the Company’s Certificate of Incorporation to effect a 1-for-10,000 reverse stock split 1-for-1,000 reverse stock split As a result of the Reverse Stock Splits, every 10,000 shares of the Company’s common stock then outstanding was combined and automatically converted into one share of the Company’s common stock every 1,000 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock The par value and other terms of the common stock were not affected by the Reverse Stock Splits. The authorized capital of the Company of 10,000,000,000 5,000,000 Effective November 5, 2021, the Company increased the authorized shares of its common stock from 10,000,000,000 50,000,000,000
Sale of Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc.	Sale of Health Technology Solutions, Inc. and Advanced Molecular Services Group, Inc. On June 25, 2021, the Company sold its subsidiaries, Health Technology Solutions, Inc. (“HTS”) and Advanced Molecular Services Group, Inc. (“AMSG”), including their subsidiaries, to InnovaQor, Inc. (“InnovaQor”), formerly known as VisualMED Clinical Solutions Corp. HTS and AMSG held Rennova’s software and genetic testing interpretation divisions. The financial results of HTS and AMSG, including the gain on sale, are reflected herein as discontinued operations. The sale is more fully discussed in Note 14.
Revenue Recognition	Revenue Recognition We recognize revenue in accordance with Accounting Standards Update (“ASU”) 2014-09, “ Revenue from Contracts with Customers (Topic 606),” ● The parties have approved the contract either in writing; orally by acknowledgement; or implicitly, based on customary business practices. ● Each party’s rights and the contract’s payment terms are identified. ● The contract has commercial substance. ● Collection is probable. We review our calculations for the realizability of gross revenues monthly to make certain that we are properly allowing for the uncollectable portion of our gross billings and that our estimates remain sensitive to variances and changes within our payer groups and within our service offerings. The contractual allowance calculation is made based on historical allowance rates for the various specific payer groups monthly with a greater weight being given to the most recent trends; this process is adjusted based on recent changes in underlying contract provisions, if any. This calculation is routinely analyzed by us based on actual allowances issued by payers and the actual payments made to determine what adjustments, if any, are needed. Our revenues generally relate to contracts with patients in which our performance obligations are to provide health care services to the patients. Revenues are recorded during the period our obligations to provide health care services are satisfied. Our performance obligations for inpatient services are generally satisfied over periods that average approximately five days, and revenues are recognized based on charges incurred in relation to total expected charges. Our performance obligations for outpatient services are generally satisfied over a period of less than one day. The contractual relationships with patients, in most cases, also involve a third-party payer (Medicare, Medicaid, managed care health plans and commercial insurance companies, including plans offered through the health insurance exchanges) and the prices for the services provided are dependent upon the terms provided by (Medicare and Medicaid) or negotiated with (managed care health plans and commercial insurance companies) the third-party payers. The payment arrangements with third-party payers for the services we provide to the related patients typically specify payments at amounts less than our standard charges. Medicare generally pays for inpatient and outpatient services at prospectively determined rates based on clinical, diagnostic and other factors. Services provided to patients having Medicaid coverage are generally paid at prospectively determined rates per discharge, per identified service or per covered member. Agreements with commercial insurance carriers and managed care and preferred provider organizations generally provide for payments based upon predetermined rates per diagnosis, per diem rates or discounted fee-for-service rates. Management continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and the frequent changes in managed care contractual terms resulting from contract renegotiations and renewals. Our net revenues are based upon the estimated amounts we expect to be entitled to receive from patients and third-party payers. Estimates of contractual allowances under managed care and commercial insurance plans are based upon the payment terms specified in the related contractual agreements. Net revenues related to uninsured patients and uninsured copayment and deductible amounts for patients who have health care coverage may have discounts applied (uninsured discounts and contractual discounts). We also record estimated implicit price concessions (based primarily on historical collection experience) related to uninsured accounts to record self-pay revenues at the estimated amounts we expect to collect. Laws and regulations governing the Medicare and Medicaid programs are complex and subject to interpretation. Estimated reimbursement amounts are adjusted in subsequent periods as cost reports are prepared and filed and as final settlements are determined (in relation to certain government programs, primarily Medicare, this is generally referred to as the “cost report” filing and settlement process). There were no adjustments to estimated Medicare and Medicaid reimbursement amounts and disproportionate-share funds related primarily to cost reports filed during the three and nine months ended September 30, 2021 and 2020. The Emergency Medical Treatment and Labor Act (“EMTALA”) requires any hospital participating in the Medicare program to conduct an appropriate medical screening examination of every person who presents to the hospital’s emergency room for treatment and, if the individual is suffering from an emergency medical condition, to either stabilize the condition or make an appropriate transfer of the individual to a facility able to handle the condition. The obligation to screen and stabilize emergency medical conditions exists regardless of an individual’s ability to pay for treatment. Federal and state laws and regulations require, and our commitment to providing quality patient care encourages, us to provide services to patients who are financially unable to pay for the health care services they receive. The federal poverty level is established by the federal government and is based on income and family size. The Company considers the poverty level in determining whether patients qualify for free or reduced cost of care. Because we do not pursue collection of amounts determined to qualify as charity care, they are not reported in net revenues. We provide discounts to uninsured patients who do not qualify for Medicaid or charity care. In implementing the uninsured discount policy, we may first attempt to provide assistance to uninsured patients to help determine whether they may qualify for Medicaid, other federal or state assistance, or charity care. If an uninsured patient does not qualify for these programs, the uninsured discount is applied. The collection of outstanding receivables for Medicare, Medicaid, managed care payers, other third-party payers and patients is our primary source of cash and is critical to our operating performance. The primary collection risks relate to uninsured patient accounts, including patient accounts for which the primary insurance carrier has paid the amounts covered by the applicable agreement, but patient responsibility amounts (deductibles and copayments) remain outstanding. Implicit price concessions relate primarily to amounts due directly from patients. Estimated implicit price concessions are recorded for all uninsured accounts, regardless of the aging of those accounts. Accounts are written off when all reasonable internal and external collection efforts have been performed. The estimates for implicit price concessions are based upon management’s assessment of historical write offs and expected net collections, business and economic conditions, trends in federal, state and private employer health care coverage and other collection indicators. Management relies on the results of detailed reviews of historical write-offs and collections at facilities that represent a majority of our revenues and accounts receivable (the “hindsight analysis”) as a primary source of information in estimating the collectability of our accounts receivable. We perform the hindsight analysis quarterly, utilizing rolling accounts receivable collection and write off data. We believe our quarterly updates to the estimated contractual allowance amounts and to the estimated implicit price concessions at each of our facilities provide reasonable estimates of our net revenues and valuation of our accounts receivable. For the three months ended September 30, 2021 and 2020, we recorded estimated contractual allowances of $ 6.8 14.0 1.9 2.2 16.2 32.9 6.2 6.2
Contractual Allowances and Doubtful Accounts Policy	Contractual Allowances and Doubtful Accounts Policy Accounts receivable are reported at realizable value, net of contractual allowances and estimated implicit price concessions (also referred to as doubtful accounts), which are estimated and recorded in the period the related revenue is recorded. The Company has a standardized approach to estimating and reviewing the collectability of its receivables based on a number of factors, including the period they have been outstanding. Historical collection and payer reimbursement experience is an integral part of the estimation process related to contractual allowances and doubtful accounts. In addition, the Company regularly assesses the state of its billing operations in order to identify issues which may impact the receivables or reserve estimates. Receivables deemed to be uncollectible are charged against the allowance for doubtful accounts at the time such receivables are written-off. Recoveries of receivables previously written-off are recorded as credits to the allowance for doubtful accounts. Revisions to the allowances for doubtful accounts are recorded as an adjustment to revenues. As required by Topic 606, after estimated implicit price concessions and contractual and related allowance adjustments to revenues of $ 8.7 million and $ 16.2 million, respectively, for the three months ended September 30, 2021 and 2020, we reported net revenues of $ 1.0 million and $ 2.0 million, respectively. After estimated implicit price concessions and contractual and related allowance adjustments to revenues of $ 22.4 million and $ 39.1 million, respectively, for the nine months ended September 30, 2021 and 2020, we reported net revenues of $ 1.3 million and $ 5.9 million, respectively. We continue to review the provisions for implicit price concessions and contractual allowances. See Note 4 – Accounts Receivable and Income Tax Refunds Receivable.
Leases in Accordance with ASU No. 2016-02	Leases in Accordance with ASU No. 2016-02 We account for leases in accordance with ASU No. 2016-02, Leases (Topic 842)
Impairment or Disposal of Long-Lived Assets	Impairment or Disposal of Long-Lived Assets We account for the impairment or disposal of long-lived assets according to the Financial Accounting Standards Board (the “FASB”) Accounting Standards Codification (“ASC”) Topic 360, Property, Plant and Equipment The Company did not record an asset impairment charge during the three and nine months ended September 30, 2021 and 2020.
Fair Value Measurements	Fair Value Measurements We define fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, we consider the principal or most advantageous market in which we would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk. We apply the following fair value hierarchy, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Inputs that are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. We applied the Level 3 fair value hierarchy in determining the fair value of the InnovaQor Series B Preferred Stock on September 30, 2021 as more fully discussed in Note 14.
Derivative Financial Instruments, Including the Adoption of ASU 2017-11	Derivative Financial Instruments, Including the Adoption of ASU 2017-11 In July 2017, the FASB issued ASU 2017-11 “Earnings Per Share (Topic 260) Distinguishing Liabilities from Equity (Topic 480) Derivatives and Hedging (Topic 815).” The amendments in Part I of this Update change the classification analysis of certain equity-linked financial instruments (or embedded features) with down round features. When determining whether certain financial instruments should be classified as liabilities or equity instruments, a down round feature no longer precludes equity classification when assessing whether the instrument is indexed to an entity’s own stock. The amendments also clarify existing disclosure requirements for equity-classified instruments. As a result, a freestanding equity-linked financial instrument (or embedded conversion option) no longer would be accounted for as a derivative liability at fair value as a result of the existence of a down round feature. For freestanding equity classified financial instruments, the amendments require entities that present earnings (loss) per share (EPS) in accordance with Topic 260 to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common stockholders in basic EPS. Convertible instruments with embedded conversion options that have down round features are now subject to the specialized guidance for contingent beneficial conversion features (in Subtopic 470-20, Debt—Debt with Conversion and Other Options), including related EPS guidance (in Topic 260). Deemed dividends represent the economic transfer of value to holders of equity-classified freestanding financial instruments when certain down round features (commonly referred to as “ratchets”) are present. The deemed dividends are presented as a reduction in net income or an increase in net loss available to common stockholders and a corresponding increase to additional paid-in-capital resulting in no change to stockholders’ equity/deficit. The incremental value of convertible debentures and warrants as a result of the down round provision features of $ 258.9 million and $ 59.8 million were recorded as deemed dividends for the three months ended September 30, 2021 and 2020, respectively. The incremental value of convertible debentures and warrants as a result of the down round provision features of $ 408.5 million and $ 59.8 million were recorded as deemed dividends for the nine months ended September 30, 2021 and 2020, respectively. In addition, we recorded deemed dividends during the three and nine months ended September 30, 2021 and 2020 as a result of: (i) the issuance of our Series M Convertible Redeemable Preferred Stock (the “Series M Preferred Stock”) on June 30, 2020; (ii) the issuance of warrants on August 27, 2021 in connection with the conversion of a portion of our Series M Preferred Stock; (iii) the issuance of our Series N Convertible Redeemable Preferred Stock (the “Series N Preferred Stock”) on August 31, 2020; and (iv) the extension of certain warrants during the three months ended September 30, 2021. Each of these transactions is more fully discussed in Note 11. See Note 10 for an additional discussion of derivative financial instruments.
Income Taxes	Income Taxes Income taxes are accounted for under the liability method of accounting for income taxes. Under the liability method, future tax liabilities and assets are recognized for the estimated future tax consequences attributable to differences between the amounts reported in the financial statement carrying amounts of assets and liabilities and their respective tax bases. Future tax assets and liabilities are measured using enacted or substantially enacted income tax rates expected to apply when the asset is realized or the liability settled. The effect of a change in income tax rates on future income tax liabilities and assets is recognized in income in the period that the change occurs. Future income tax assets are recognized to the extent that they are considered more likely than not to be realized. When projected future taxable income is insufficient to provide for the realization of deferred tax assets, the Company recognizes a valuation allowance. In accordance with U.S. GAAP, the Company is required to determine whether a tax position of the Company is more likely than not to be sustained upon examination by the applicable taxing authority, including resolution of any related appeals or litigation processes, based on the technical merits of the position. The tax benefit to be recognized is measured as the largest amount of benefit that is greater than fifty percent likely of being realized upon ultimate settlement. Derecognition of a tax benefit previously recognized could result in the Company recording a tax liability that would reduce net assets. Based on its analysis, the Company has determined that it has not incurred any liability for unrecognized tax benefits as of September 30, 2021 and December 31, 2020.
Earnings (Loss) Per Share	Earnings (Loss) Per Share The Company reports earnings (loss) per share in accordance with ASC Topic 260, “Earnings Per Share,” which establishes standards for computing and presenting earnings (loss) per share. Basic earnings (loss) per share of common stock is calculated by dividing net earnings (loss) available to common stockholders by the weighted-average shares of common stock outstanding during the period, without consideration of common stock equivalents. Diluted earnings (loss) per share is calculated by adjusting the weighted-average shares of common stock outstanding for the dilutive effect of common stock equivalents, including preferred stock, convertible debt, stock options and warrants outstanding for the period as determined using the treasury stock method. For purposes of the diluted net loss per share calculation, common stock equivalents are excluded from the calculation when their effect would be anti-dilutive. See Note 3 for the computation of the loss per share for the three and nine months ended September 30, 2021 and 2020.

Loss Per Share (Tables)

Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2021
Earnings Per Share [Abstract]
Schedule of Earnings Per Share Available to Common stockholders	The following table sets forth the computation of the Company’s basic and diluted net loss per share available to common stockholders during the three and nine months ended September 30, 2021 and 2020 (unaudited): Schedule of Earnings Per Share Available to Common stockholders 2021 2020 2021 2020 Three Months Ended September 30, Nine Months Ended September 30, 2021 2020 2021 2020 Numerator Net income (loss) from continuing operations $ 785,565 $ (6,025,885 ) $ (4,371,860 ) $ (9,697,922 ) Deemed dividends (259,530,999 ) (63,544,950 ) (409,142,478 ) (66,695,318 ) Net loss available to common stockholders, continuing operations (258,745,434 ) (69,570,835 ) (413,514,338 ) (76,393,240 ) Net income (loss) from discontinued operations 545,399 (166,180 ) 10,880,148 (164,293 ) Net loss available to common stockholders $ (258,200,035 ) $ (69,737,015 ) $ (402,634,190 ) $ (76,557,533 ) Denominator Basic and diluted weighted average shares of common stock outstanding 438,998,913 1,284 150,459,817 1,086 Loss per share available to common stockholders- basic and diluted: Continuing operations $ (0.59 ) $ (54,182.89 ) $ (2.75 ) $ (70,343.68 ) Discontinued operations $ 0.00 $ (129.42 ) $ 0.07 $ (151.28 ) Total basic and diluted $ (0.59 ) $ (54,312.31 ) $ (2.68 ) $ (70,494.96 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Diluted loss per share excludes all dilutive potential shares if their effect is anti-dilutive. As of September 30, 2021 and 2020, the following potential common stock equivalents were excluded from the calculation of diluted loss per share as their effect was anti-dilutive: Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share 2021 2020 September 30, 2021 2020 Warrants 182,663,835,039 335,461 Convertible preferred stock 89,770,798,934 313,808 Convertible debentures 9,664,944,444 51,133 Stock options 26 26 Dilutive potential shares 282,099,578,443 700,428

Accounts Receivable and Incom_2

Accounts Receivable and Income Tax Refunds Receivable (Tables)	9 Months Ended
	Sep. 30, 2021
Receivables [Abstract]
Schedule of Accounts Receivable	Accounts receivable at September 30, 2021 (unaudited) and December 31, 2020 consisted of the following: Schedule of Accounts Receivable September 30, December 31, September 30, December 31, 2021 2020 Accounts receivable $ 9,626,490 $ 16,922,576 Less: Allowance for contractual obligations (6,788,342 ) (13,185,843 ) Allowance for doubtful accounts (992,330 ) (1,513,827 ) Accounts receivable owed under settlement/sales agreements (847,059 ) (1,723,452 ) Accounts receivable, net $ 998,759 $ 499,454

Accrued Expenses (Tables)

Accrued Expenses (Tables)	9 Months Ended
	Sep. 30, 2021
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued expenses at September 30, 2021 (unaudited) and December 31, 2020 consisted of the following: Schedule of Accrued Expenses September 30, December 31, 2021 2020 Accrued payroll and related liabilities $ 9,152,027 $ 8,263,940 HHS Provider Relief Funds (See Note 2) - 4,400,000 Accrued interest 5,989,653 4,728,942 Accrued legal 1,097,318 1,097,318 Other accrued expenses 1,203,166 645,369 Accrued expenses $ 17,442,164 $ 19,135,569

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Notes Payable	The Company and its subsidiaries are party to a number of loans with third parties and related parties. At September 30, 2021 (unaudited) and December 31, 2020, notes payable consisted of the following: Schedule of Notes Payable Notes Payable – Third Parties September 30, December 31, Loan payable to TCA Global Master Fund, L.P. (“TCA”) in the original principal amount of $ 3 16 Payable in various installments through May 4, 2022 (balance at September 30, 2021 as per settlement agreement – See Note 13) $ 500,000 $ 1,741,893 Notes payable to CommerceNet and Jay Tenenbaum in the original principal amount of $ 500,000 6 Principal and interest payments due annually from July 12, 2015 through July 12, 2017 291,557 297,068 Note payable to Anthony O’Killough dated September 27, 2019 in the original principal amount of $ 1.9 0.3 0.1 Payment due in installments through November 2020 1,450,000 1,450,000 Notes payable under the PPP loans issued on April 20, 2020 through May 1, 2020 bearing interest at a rate of 1 principal and interest payments are due monthly beginning sixteen months from the date of issuance and the notes mature 40 months from the date of issuance. 1,358,923 2,385,921 Installment promissory note dated January 29, 2020, less original issue discount of $ 0.1 22,500 34,000 - 108,350 Notes payable dated January 31, 2021 and February 16, 2021 due six months from the date of issuance. The notes bear interest at 10 100 245,000 - Notes payable to Western Healthcare, LLC dated August 10, 2021, in the aggregate principal amount of $ 2.4 18 0.2 2,152,961 - Warrant pre-payment promissory notes dated February 25, 2021, April 9, 2021, April 16, 2021 and April 22, 2021, non-interest bearing, $ 1,100,000 100,000 payable 12 months from the date of issuance 1,052,837 - Note payable 7,051,278 5,983,232 Less current portion (7,051,278 ) (4,786,976 ) Notes payable - third parties, net of current portion $ - $ 1,196,256
Schedule of Notes Payable - Related Parties	Schedule of Notes Payable - Related Parties September 30, December 31, (unaudited) Note payable to Christopher Diamantis due on demand and bearing interest at 10 $ 2,627,000 $ 2,097,000 Total note payable, related party 2,627,000 2,097,000 Less current portion of note payable, related party (2,627,000 ) (2,097,000 ) Total note payable, related party, net of current portion $ - $ -

Debentures (Tables)

Debentures (Tables)	9 Months Ended
	Sep. 30, 2021
Debt Disclosure [Abstract]
Schedule of Debentures	The carrying amount of all outstanding debentures as of September 30, 2021 and December 31, 2020 is as follows: Schedule of Debentures September 30, 2021 December 31, 2020 (unaudited) Debentures $ 12,690,539 $ 12,690,539 Less current portion (12,690,539 ) (12,690,539 ) Debentures, net of current portion $ - $ -

Finance and Operating Lease O_2

Finance and Operating Lease Obligations (Tables)	9 Months Ended
	Sep. 30, 2021
Finance And Operating Lease Obligations
Schedule of Lease-related Assets and Liabilities	The following table presents our lease-related assets and liabilities at September 30, 2021 (unaudited) and December 31, 2020: Schedule of Lease-related Assets and Liabilities Balance Sheet Classification September 30, 2021 December 31, 2020 Assets: Operating leases Right-of-use operating lease assets $ 877,412 $ 1,000,272 Finance leases Property and equipment, net 220,461 249,985 Total lease assets $ 1,097,873 $ 1,250,257 Liabilities: Current: Operating leases Right-of-use operating lease obligations $ 237,026 $ 172,952 Finance leases Current liabilities 220,461 249,985 Noncurrent: Operating leases Right-of-use operating lease obligations 640,386 827,320 Total lease liabilities $ 1,097,873 $ 1,250,257 Weighted-average remaining term: Operating leases 3.50 4.17 Finance leases 0 years 0 years Weighted-average discount rate: Operating leases 13.0 % 13.0 % Finance leases 4.9 % 4.9 %
Schedule of Information Related to Lease Expense for Finance and Operating Leases	The following table presents certain information related to lease expense for finance and operating leases for the three months and nine months ended September 30, 2021 and 2020: Schedule of Information Related to Lease Expense for Finance and Operating Leases Three Months Ended September 30, 2021 Three Months Ended September 30, 2020 Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Finance lease expense: Depreciation/amortization of leased assets $ - $ - $ - $ 26,349 Interest on lease liabilities - - - 9,455 Operating leases: Short-term lease expense (1) 44,342 49,196 151,025 219,138 Total lease expense $ 44,342 $ 49,196 $ 151,025 $ 254,942 (1) Expenses are included in general and administrative expenses in the consolidated statements of operations.
Schedule of Supplemental Cash Flow Information	The following table presents supplemental cash flow information for the nine months ended September 30, 2021 and 2020: Schedule of Supplemental Cash Flow Information Nine Months Ended September 30, 2021 Nine Months Ended September 30, 2020 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows for operating leases $ 168,923 $ 98,374 Operating cash flows for finance leases - 9,455 Financing cash flows for finance lease payments 29,524 200,709
Schedule of Future Minimum Rentals Under Right-to-use Operating and Finance Leases	Aggregate future minimum lease payments under right-of-use operating and finance leases are as follows: Schedule of Future Minimum Rentals Under Right-to-use Operating and Finance Leases Right-of-Use Operating Leases Finance Leases Twelve months ended September 30, 2022 $ 337,357 $ 224,252 Twelve months ended September 30, 2023 307,082 - Twelve months ended September 30, 2024 217,839 - Twelve months ended September 30, 2025 223,795 - Twelve months ended September 30, 2026 18,650 - Thereafter - - Total 1,104,723 224,252 Less interest - - Present value of minimum lease payments $ 1,104,723 $ 224,252 Less current portion of lease obligations (227,311 ) (3,791 ) Lease obligations, net of current portion $ 877,412 $ 220,461

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2021
Fair Value Disclosures [Abstract]
Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis	The following table sets forth the financial assets and liabilities carried at fair value measured on a recurring basis as of September 30, 2021 and December 31, 2020: Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis Level 1 Level 2 Level 3 Total (unaudited) As of December 31, 2020: InnovaQor Series B Preferred Stock $ - $ - $ - $ - Embedded conversion option of debenture - $ - $ 455,336 $ 455,336 Total $ - $ - $ 455,336 $ 455,336 As of September 30, 2021: InnovaQor Series B Preferred Stock $ - $ - $ 9,016,072 $ 9,016,072 Embedded conversion option of debenture - - 455,336 455,336 Total $ - $ - $ 9,471,408 $ 9,471,408

Stockholders_ Deficit (Tables)

Stockholders’ Deficit (Tables)	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
Schedule of Warrants Activity	The following summarizes the information related to the number of shares of common stock issuable under outstanding warrants during the nine months ended September 30, 2021: Schedule of Warrants Activity Number of Shares of Common Stock Issuable for Warrants Weighted average exercise price Balance at December 31, 2020 4,571,165 $ 19.99 Issuance of warrants 47,500,000 0.007 Expiration of warrants (44,078,213 ) (0.3110 ) Increase in number of shares of common stock issuable under warrants during the period as a result of down round provisions 182,655,951,726 - Balance at September 30, 2021 182,663,835,038 $ 0.00043

Supplemental Disclosure of Ca_2

Supplemental Disclosure of Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2021
Supplemental Cash Flow Elements [Abstract]
Schedule of Supplemental Disclosure of Cash Flow Information	Schedule of Supplemental Disclosure of Cash Flow Information 2021 2020 Nine Months Ended September 30, 2021 2020 Cash paid for interest $ - $ 64,454 Cash paid for income taxes $ 281,025 $ - Non-cash investing and financing activities: Preferred stock of InnovaQor received from the sale of HTS and AMSG $ 9,117,500 $ - Net liabilities of HTS and AMSG transferred to InnovaQor 2,227,152 - Settlement of liability with InnovaQor preferred stock 60,714 - Issuance of notes payable in settlement of accounts payable and accrued expenses 2,352,961 - Series I-2 Preferred Stock converted into common stock - 277,994 Exchange of Series K Preferred Stock for Series L Preferred Stock - (2,500 ) Issuance of Series L Preferred Stock - 2,500 Issuance of Series M Preferred Stock in exchange for related party loans and accrued interest - 22,000,000 Loans and accrued interest exchanged for Series M Preferred Stock - (18,849,632 ) Deemed dividend from exchange of loans and accrued interest for Series M Preferred Stock - 3,150,368 Series M Preferred Stock converted/exchanged into common stock 1,189,650 - Deemed dividends from issuance of common stock warrants under exchange agreement 341,525 - Issuance of Series N Preferred Stock in exchange for debentures, accrued interest and Series I-1 and Series I-2 Preferred Stock - 30,435,519 Debentures, accrued interest and Series I-1 and Series I-2 Preferred Stock exchanged for Series N Preferred Stock - (19,342,322 ) Series N Preferred Stock converted into common stock 18,355,507 58 Deemed dividends from the issuance of Series N Preferred Stock - 3,720,718 Deemed dividends for trigger of down round provisions 408,509,361 59,824,232 Deemed dividends from extension of common stock warrants 291,592 - Original issue discounts on debt 52,836 108,958

Discontinued Operations (Tables

Discontinued Operations (Tables)	9 Months Ended
	Sep. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Discontinued Operation of Balance Sheet and Operation Statement	Carrying amounts of major classes of assets and liabilities sold or included as part of discontinued operations in the consolidated balance sheets as of September 30, 2021 and December 31, 2020 consisted of the following: Schedule of Discontinued Operation of Balance Sheet and Operation Statement HTS and AMSG Assets and Liabilities: September 30, 2021 December 31, 2020 (unaudited) Cash $ $ 31,294 Accounts receivable, net - 151,363 Prepaid expenses and other current assets - 1,717 Current assets classified as held for sale $ - $ 184,374 Property and equipment, net $ - $ 685 Deposits - - Right-of-use assets - - Non-current assets classified as held for sale $ - $ 685 Accounts payable and checks issued in excess of bank balance $ - $ 726,220 Accrued expenses - 1,308,283 Current portion of right-of-use operating lease obligation - - Current portion of notes payable - 168,751 Current liabilities classified as held for sale $ - $ 2,203,254 Note payable $ - $ 69,267 Right-of-use operating lease obligation - - Non-current liabilities classified as held for sale $ - $ 69,267 EPIC Reference Labs, Inc. and Other Subsidiaries Assets and Liabilities: September 30, December 31, (unaudited) Cash $ - $ 136 Accounts receivable, net - - Prepaid expenses and other current assets - - Current assets classified as held for sale $ - $ 136 Property and equipment, net $ - $ - Deposits 5,014 100,014 Right-of-use assets - 100,116 Non-current assets classified as held for sale $ 5,014 $ 200,130 Accounts payable and checks in excess of bank balance $ 1,111,557 $ 1,185,158 Accrued expenses 336,410 334,667 Current portion of right-of-use operating lease obligation - 91,166 Current portion of notes payable - - Current liabilities classified as held for sale $ 1,447,967 $ 1,610,991 Note payable $ - $ - Right-of-use operating lease obligation - 8,950 Non-current liabilities classified as held for sale $ - $ 8,950 Consolidated Discontinued Operations Assets and Liabilities: September 30, December 31, (unaudited) Cash $ - $ 31,430 Accounts receivable, net - 151,363 Prepaid expenses and other current assets - 1,717 Current assets classified as held for sale $ - $ 184,510 Property and equipment, net $ - $ 685 Deposits 5,014 100,014 Right-of-use assets - 100,116 Non-current assets classified as held for sale $ 5,014 $ 200,815 Accounts payable and checks issued in excess of bank balance $ 1,111,557 $ 1,911,378 Accrued expenses 336,410 1,642,950 Current portion of right-of-use operating lease obligation - 91,166 Current portion of notes payable - 168,751 Current liabilities classified as held for sale $ 1,447,967 $ 3,814,245 Note payable $ - $ 69,267 Right-of-use operating lease obligation - 8,950 Non-current liabilities classified as held for sale $ - $ 78,217 Major line items constituting income (loss) from discontinued operations in the consolidated statements of operations for the three and nine months ended September 30, 2021 and 2020 consisted of the following (unaudited): HTS and AMSG Income (Loss) from Discontinued Operations (unaudited): Three Months Three Months Ended Nine Months Nine Months Revenue from services $ - $ 174,941 $ 216,941 $ 437,119 Cost of services - 390 2,386 11,379 Gross profit - 174,551 214,555 425,740 Operating expenses - (258,710 ) (551,296 ) (509,989 ) Other income (expense) - (9,636 ) (9,577 ) (61,067 ) Gain on sale 576,787 - 11,303,939 - Provision for income taxes - - - - Income (loss) from discontinued operations $ 576,787 $ (93,795 ) $ 10,957,621 $ (145,316 ) The fair value of the InnovaQor Series B Preferred Stock that the Company received as consideration for the sale of $9.1 million was based on a third-party valuation using the Option Price Method (the “OPM”). The OPM treats common and preferred interests as call options on the equity value of the subject company, with exercise prices based on the liquidation preference of the preferred interests and participation thresholds for subordinated classes. The common interest is modeled as a call option that gives its owner the right but not the obligation to buy the enterprise value at a predetermined or exercise price. In the model, the exercise price is based on a comparison with the enterprise value rather than, as in the case of a “regular” call option, a comparison with a per share stock price. Thus, the common interest is considered to be a call option with a claim on the enterprise at an exercise price equal to the remaining value immediately after the preferred interests are liquidated. The Black Scholes model was used to price the call options. The assumptions used were: risk free rate of 0.84%; volatility of 250.0%; and exit period of 5 years. Lastly, a discount rate of 35% was applied due to the lack of marketability of the InnovaQor Series B Preferred Stock and the underlying liquidity of InnovaQor’s common stock. EPIC Reference Labs, Inc. and Other Subsidiaries Income (Loss) from Discontinued Operations (unaudited): Three Months Three Months Ended Nine Months Nine Months Revenue from services $ - $ - $ - $ 441 Cost of services - - - - Gross profit - - - 441 Operating expenses (31,388 ) (41,439 ) (126,243 ) (106,704 ) Other income (expense) - (30,946 ) 48,770 87,286 Gain on sale - - - - Provision for income taxes - - - - Loss from discontinued operations $ (31,388 ) $ (72,385 ) $ (77,473 ) $ (18,977 ) Consolidated Income (Loss) from Discontinued Operations (unaudited): Three Months Three Months Ended Nine Months Nine Months Revenue from services $ - $ 174,941 $ 216,941 $ 437,560 Cost of services - 390 2,386 11,379 Gross profit - 174,551 214,555 426,181 Operating expenses (31,388 ) (300,149 ) (677,539 ) (616,693 ) Other income (expense) - (40,582 ) 39,193 26,219 Gain on sale 576,787 - 11,303,939 - Provision for income taxes - - - - Income (loss) from discontinued operations $ 545,399 $ (166,180 ) $ 10,880,148 $ (164,293 )

Subsequent Events (Tables)

Subsequent Events (Tables)	9 Months Ended
	Sep. 30, 2021
Subsequent Events [Abstract]
Schedule of Dilutive Effect of Various Potential Common Shares	The following table presents the potential dilutive effect of our various equity-linked instruments as of November 10, 2021: Schedule of Dilutive Effect of Various Potential Common Shares November 10, Shares of common stock outstanding 13,491,000,000 Dilutive potential shares: Convertible preferred stock 174,319,763,738 Warrants 273,995,752,554 Convertible debt 14,443,166,667 Stock options 26 Total dilutive potential shares of common stock, including outstanding common stock 476,249,682,985

Organization and Summary of S_3

Organization and Summary of Significant Accounting Policies (Details Narrative) - USD ($)	Jul. 16, 2021	Jul. 08, 2021	Jul. 31, 2020	Jul. 22, 2020	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Nov. 05, 2021	Dec. 31, 2020
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Reverse Stock Split	every 1,000 shares of the Company’s then outstanding common stock was combined and automatically converted into one share of the Company’s common stock		As a result of the Reverse Stock Splits, every 10,000 shares of the Company’s common stock then outstanding was combined and automatically converted into one share of the Company’s common stock
Common stock shares authorized					10,000,000,000				10,000,000,000		50,000,000,000	10,000,000,000
Preferred stock shares authorized					5,000,000				5,000,000
Estimated contractual allowances					$ 6,800,000		$ 14,000,000		$ 16,200,000	$ 32,900,000
Bad debt expenses					1,900,000	$ 1,900,000	2,200,000	$ 2,200,000	6,200,000	6,200,000
Allowance for adjustment of revenue					8,700,000		16,200,000		22,400,000	39,100,000
Revenue from Contract with Customer, Excluding Assessed Tax					1,010,245		1,950,698		1,288,402	5,860,807
Deemed dividend					$ 258,900,000		$ 59,800,000		$ 408,500,000	$ 59,800,000
Forecast [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Common stock shares authorized											50,000,000,000
Board Of Directors [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Reverse Stock Split		1-for-1,000 reverse stock split		1-for-10,000 reverse stock split
Preferred stock shares authorized					5,000,000				5,000,000

Liquidity and Financial Condi_2

Liquidity and Financial Condition (Details Narrative) - USD ($)	3 Months Ended				9 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Mar. 31, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 25, 2021	Dec. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019
Relief funds					$ 12,500,000
Revenue recognized amount					12,400,000
Revenue recognized	$ 500,000	$ 7,500,000	$ 2,500,000		4,400,000	$ 8,000,000
Working capital		54,300,000
Stockholders deficit	37,509,709	41,340,429	52,911,746	$ 40,540,193	37,509,709	40,540,193		$ 49,017,752	$ 61,315,239	$ 82,286,499	$ 76,519,721
Loss from continuing operations	$ 2,400,000			$ 4,200,000	10,200,000	11,300,000
Cash used in operating activities					5,689,943	$ 13,522,634
Advanced Molecular Services Group And Health Technology Solutions Inc [Member] | Visual M E D [Member]
Disposal Group, Including Discontinued Operation, Liabilities							$ 2,200,000
Advanced Molecular Services Group And Health Technology Solutions Inc [Member] | Visual M E D [Member] | Series B Preferred Stock [Member]
Disposal Group, Including Discontinued Operation, Consideration							$ 9,100,000
Paycheck Protection Program Loan [Member]
Revenue recognized			$ 100,000
Public Health And Social Services Emergency Fund [Member]
Relief funds					$ 100,000,000,000
Provider Relief Funds [Member]
Revenue recognized		$ 1,900,000

Schedule of Earnings Per Share

Schedule of Earnings Per Share Available to Common stockholders (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Earnings Per Share [Abstract]
Net income (loss) from continuing operations	$ 785,565	$ (6,025,885)	$ (4,371,860)	$ (9,697,922)
Deemed dividends	(259,530,999)	(63,544,950)	(409,142,478)	(66,695,318)
Net loss available to common stockholders, continuing operations	(258,745,434)	(69,570,835)	(413,514,338)	(76,393,240)
Net income (loss) from discontinued operations	545,399	(166,180)	10,880,148	(164,293)
Net loss available to common stockholders	$ (258,200,035)	$ (69,737,015)	$ (402,634,190)	$ (76,557,533)
Basic and diluted weighted average shares of common stock outstanding	438,998,913	1,284	150,459,817	1,086
Continuing operations	$ (0.59)	$ (54,182.89)	$ (2.75)	$ (70,343.68)
Discontinued operations	0	(129.42)	0.07	(151.28)
Total basic and diluted	$ (0.59)	$ (54,312.31)	$ (2.68)	$ (70,494.96)

Schedule of Antidilutive Securi

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential shares	282,099,578,443	700,428
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential shares	182,663,835,039	335,461
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential shares	89,770,798,934	313,808
Convertible Debt Securities [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential shares	9,664,944,444	51,133
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Dilutive potential shares	26	26

Loss Per Share (Details Narrati

Loss Per Share (Details Narrative) - shares	Nov. 10, 2021	Sep. 30, 2021	Dec. 31, 2020
Subsequent Event [Line Items]
Common stock shares outstanding		4,777,350,000	39,648
Subsequent Event [Member]
Subsequent Event [Line Items]
Common stock shares outstanding	476,200,000,000

Schedule of Accounts Receivable

Schedule of Accounts Receivable (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Receivables [Abstract]
Accounts receivable	$ 9,626,490	$ 16,922,576
Allowance for contractual obligations	(6,788,342)	(13,185,843)
Allowance for doubtful accounts	(992,330)	(1,513,827)
Accounts receivable owed under settlement/sales agreements	(847,059)	(1,723,452)
Accounts receivable, net	$ 998,759	$ 499,454

Accounts Receivable and Incom_3

Accounts Receivable and Income Tax Refunds Receivable (Details Narrative) - USD ($)	3 Months Ended				6 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Jun. 30, 2021	Sep. 30, 2020	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Defined Benefit Plan Disclosure [Line Items]
Percentage of accounts receivable						80.80%		86.90%
Accounts Receivable, Credit Loss Expense (Reversal)	$ 1,900,000	$ 1,900,000	$ 2,200,000	$ 2,200,000		$ 6,200,000	$ 6,200,000
Accounts Receivable, Allowance for Credit Loss	992,330					992,330		$ 1,513,827
Accounts Receivable, Allowance for Credit Loss, Period Increase (Decrease)						500,000
Accounts Receivable, Sale								3,300,000
Proceeds from Accounts Receivable Securitization								2,200,000
Loan Processing Fee								100,000
Gain (Loss) on Sale of Accounts Receivable							(591,563)	1,200,000
Accounts Receivable, after Allowance for Credit Loss								1,700,000
Amount need to be paid						500,000
Gain from legal settlements	3,157,203		$ (23,652)			3,179,393	$ 1,096,613
Income tax refunds					$ 0	300,000
Federal Net Operating Losses [Member]
Defined Benefit Plan Disclosure [Line Items]
Income tax refunds						1,100,000		1,400,000
Other Net Operating Losses [Member]
Defined Benefit Plan Disclosure [Line Items]
Income tax refunds						300,000		$ 1,100,000
Two Thousand And Fifteen Federal Tax Return [Member]
Defined Benefit Plan Disclosure [Line Items]
Income tax refunds						300,000
Three Funding Parties [Member] | Sales Agreements [Member]
Defined Benefit Plan Disclosure [Line Items]
Amount need to be paid						900,000
Monthly payments						52,941
Gain from legal settlements	$ 600,000					$ 600,000

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued payroll and related liabilities	$ 9,152,027	$ 8,263,940
HHS Provider Relief Funds (See Note 2)		4,400,000
Accrued interest	5,989,653	4,728,942
Accrued legal	1,097,318	1,097,318
Other accrued expenses	1,203,166	645,369
Accrued expenses	$ 17,442,164	$ 19,135,569

Accrued Expenses (Details Narra

Accrued Expenses (Details Narrative) - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Employee-related Liabilities	$ 2.7	$ 2.5
Accrued Payroll Taxes	$ 5	$ 4.4

Schedule of Notes Payable (Deta

Schedule of Notes Payable (Details) (Parenthetical) - USD ($)	6 Months Ended	9 Months Ended	12 Months Ended
	Jun. 30, 2021	Sep. 30, 2021	Dec. 31, 2020
Notes Payable Third Parties One [Member]
Short-term Debt [Line Items]
Original principal amount			$ 3,000,000
Debt instruments interest rate		16.00%
Debt maturity description		Payable in various installments through May 4, 2022 (balance at September 30, 2021 as per settlement agreement – See Note 13)
Notes Payable Third Parties Two[Member]
Short-term Debt [Line Items]
Original principal amount		$ 500,000	$ 500,000
Debt instruments interest rate		6.00%	6.00%
Debt maturity description		Principal and interest payments due annually from July 12, 2015 through July 12, 2017	Principal and interest payments due annually from July 12, 2015 through July 12, 2017
Notes Payable Third Parties Three[Member]
Short-term Debt [Line Items]
Original principal amount		$ 1,900,000	$ 1,900,000
Debt maturity description		Payment due in installments through November 2020	Payment due in installments through November 2020.
Original issue discount		$ 300,000	$ 300,000
Financing fees debt		$ 100,000	$ 100,000
Notes Payable Third Parties Four [Member] | Paycheck Protection Program [Member]
Short-term Debt [Line Items]
Debt instruments interest rate		1.00%	1.00%
Debt maturity description		principal and interest payments are due monthly beginning sixteen months from the date of issuance and the notes mature 40 months from the date of issuance.	principal and interest payments are due monthly beginning sixteen months from the date of issuance and the notes mature 40 months from the date of issuance.
Notes Payable Third PartiesFive [Member]
Short-term Debt [Line Items]
Original principal amount			$ 100,000
Notes Payable Third PartiesFive [Member] | Minimum [Member]
Short-term Debt [Line Items]
Debt instrument periodic payment	$ 22,500		22,500
Notes Payable Third PartiesFive [Member] | Maximum [Member]
Short-term Debt [Line Items]
Debt instrument periodic payment		$ 34,000	$ 34,000
Notes Payable Third Parties Six [Member]
Short-term Debt [Line Items]
Debt instruments interest rate			10.00%
Share receivable			100
Notes Payable Third Parties Seven [Member]
Short-term Debt [Line Items]
Original principal amount		$ 2,400,000	$ 2,400,000
Debt maturity description		payable 12 months from the date of issuance	payable 12 months from the date of issuance
Debt instrument periodic payment		$ 200,000	$ 200,000
Notes Payable Third Parties Seven [Member] | Paycheck Protection Program [Member]
Short-term Debt [Line Items]
Debt instruments interest rate		18.00%	18.00%

Schedule of Notes Payable (De_2

Schedule of Notes Payable (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Note payable	$ 7,051,278	$ 5,983,232
Less current portion	(7,051,278)	(4,786,976)
Notes payable - third parties, net of current portion		1,196,256
Notes Payable Third Parties One [Member]
Short-term Debt [Line Items]
Note payable	500,000	1,741,893
Original principal amount		3,000,000
Notes Payable Third Parties Two[Member]
Short-term Debt [Line Items]
Note payable	291,557	297,068
Original principal amount	500,000	500,000
Notes Payable Third Parties Three[Member]
Short-term Debt [Line Items]
Note payable	1,450,000	1,450,000
Original principal amount	1,900,000	1,900,000
Original issue discount	300,000	300,000
Notes Payable Third Parties Four [Member]
Short-term Debt [Line Items]
Note payable	1,358,923	2,385,921
Notes Payable Third PartiesFive [Member]
Short-term Debt [Line Items]
Note payable		108,350
Original principal amount		100,000
Notes Payable Third Parties Six [Member]
Short-term Debt [Line Items]
Note payable	245,000
Notes Payable Third Parties Seven [Member]
Short-term Debt [Line Items]
Note payable	2,152,961
Original principal amount	2,400,000	2,400,000
Notes Payable Third Parties Eight [Member]
Short-term Debt [Line Items]
Note payable	1,052,837
Original principal amount	1,100,000	1,100,000
Original issue discount	$ 100,000	$ 100,000

Schedule of Notes Payable - Rel

Schedule of Notes Payable - Related Parties (Details) (Parenthetical)	Sep. 30, 2021	Dec. 31, 2020
MrChristopher Diamantis [Member]
Deferred Compensation Arrangement with Individual, Excluding Share-based Payments and Postretirement Benefits [Line Items]
Debt interest rate	10.00%	10.00%

Schedule of Notes Payable - R_2

Schedule of Notes Payable - Related Parties (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Total note payable, related party	$ 2,627,000	$ 2,097,000
Less current portion of note payable, related party	(2,627,000)	(2,097,000)
Total note payable, related party, net of current portion
Loan Payablet To Christopher Diamantis [Member]
Short-term Debt [Line Items]
Total note payable, related party	$ 2,627,000	$ 2,097,000

Schedule of Debentures (Details

Schedule of Debentures (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Debentures	$ 12,690,539	$ 12,690,539
Less current portion	(12,690,539)	(12,690,539)
Debentures, net of current portion

Notes Payable (Details Narrativ

Notes Payable (Details Narrative) - USD ($)	Sep. 14, 2021	May 01, 2020	Jan. 29, 2020	Sep. 27, 2019	Aug. 31, 2021	May 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Jun. 30, 2021	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2021	Nov. 03, 2021	Aug. 10, 2021	May 05, 2021	Apr. 16, 2021	Dec. 31, 2020	Apr. 20, 2020	Feb. 29, 2020	Nov. 03, 2016
Short-term Debt [Line Items]
Amount yet be paid related party										$ 500,000
Accrued interest payable							$ 200,000			200,000
Repayments of Debt											$ 920,000
Notes Payable							7,051,278			7,051,278							$ 5,983,232
Proceeds from Notes Payable										1,245,000	1,198,835
Amortization of Debt Discount (Premium)										113,552	108,958
Repayments of loan										360,000	4,187,387
Debt instrumen carrying value							$ 12,690,539			12,690,539							$ 12,690,539
Investor [Member]
Short-term Debt [Line Items]
Principal amount																$ 1,100,000
Proceeds from issuance of debt										$ 1,000,000
Debt Instrument, Interest Rate, Stated Percentage							18.00%			18.00%
Debt Conversion, Original Debt, Amount										$ 100,000
Amortization of Debt Discount (Premium)							$ 25,205			$ 52,836
Diamantis [Member]
Short-term Debt [Line Items]
Accrued interest payable									$ 700,000
Payment amount				$ 1,000,000
Principal amount				1,900,000					1,500,000
Repayments of Debt						$ 2,200,000			450,000
Proceeds from issuance of debt				1,500,000					$ 2,200,000
Original issue discount				300,000
Debt Issuance Costs, Net				$ 100,000
Debt Instrument, Maturity Date				Nov. 8, 2019
Notes Payable																			$ 2,200,000
MrChristopher Diamantis [Member]
Short-term Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage							10.00%			10.00%							10.00%
Loans payable							$ 900,000	$ 4,600,000		$ 900,000	4,600,000
Repayments of loan										400,000	4,200,000
Debt instrumen carrying value							18,800,000			18,800,000
MrDiamantis [Member]
Short-term Debt [Line Items]
Accrued interest payable							$ 300,000			300,000		$ 200,000
Repayments of Debt										$ 1,500,000
Debt Instrument, Interest Rate, Stated Percentage							10.00%			10.00%
Accrued and unpaid interest							$ 0	$ 55,000		$ 100,000	$ 500,000
Tegal Notes [Member]
Short-term Debt [Line Items]
Accrued interest payable																				$ 43,000
Principal amount																				$ 341,612
Repayments of Debt										50,055
Remaining Principal [Member] | Diamantis [Member]
Short-term Debt [Line Items]
Payment amount				$ 900,000
Debt Instrument, Maturity Date				Dec. 26, 2019
PPP Notes [Member]
Short-term Debt [Line Items]
Proceeds from Notes Payable		$ 2,400,000
Debt Instrument, Term		2 years
Debt Instrument, Interest Rate, Stated Percentage																		1.00%
PPP Notes [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Principal amount													$ 800,000
Ponte Note [Member]
Short-term Debt [Line Items]
Principal amount			$ 1,200,000
Original issue discount			$ 100,000
Debt instrument maturity date description			due on or before February 5, 2020 through on or before October 21, 2020, the maturity date.
Late payment fee percentage			10.00%
Ponte Note [Member] | Minimum [Member]
Short-term Debt [Line Items]
Payment amount			$ 22,500
Ponte Note [Member] | Maximum [Member]
Short-term Debt [Line Items]
Payment amount			$ 34,000
Installment Note [Member]
Short-term Debt [Line Items]
Penalties							9,850			9,850
Settlement Agreement [Member]
Short-term Debt [Line Items]
Principal amount															$ 125,000
TCA Debenture [Member]
Short-term Debt [Line Items]
Accrued interest payable							$ 2,200,000			2,200,000
Payment amount										300,000
Monthly installments										$ 50,000
Paycheck Protection Program [Member]
Short-term Debt [Line Items]
Accrued interest payable																		$ 15,000
Principal amount																		$ 1,000,000
Paycheck Protection Program [Member] | Subsequent Event [Member]
Short-term Debt [Line Items]
Debt instrument forgiven													$ 800,000
Settlement Agreement [Member]
Short-term Debt [Line Items]
Repayments of loan	$ 52,941
Settlement Agreement [Member] | Western Health Care [Member]
Short-term Debt [Line Items]
Monthly installments					$ 200,000
Principal amount														$ 2,400,000
Proceeds from issuance of debt					$ 200,000
Debt Instrument, Interest Rate, Stated Percentage														18.00%

Debentures (Details Narrative)

Debentures (Details Narrative) $ / shares in Units, shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2021USD ($)$ / shares	Sep. 30, 2020USD ($)	Sep. 30, 2021USD ($)shares$ / shares	Sep. 30, 2020USD ($)	Dec. 31, 2020USD ($)
Short-term Debt [Line Items]
Long-term Debt					$ 12,700,000
Long-term Debt, Gross	$ 12,690,539		$ 12,690,539		$ 12,690,539
Debenture [Member]
Short-term Debt [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	18.00%		18.00%
Debentures [Member]
Short-term Debt [Line Items]
Interest expenses on debentures	$ 600,000	$ 1,500,000	$ 1,700,000	$ 5,400,000
Convertible Debentures [Member]
Short-term Debt [Line Items]
Long-term Debt, Gross	$ 2,600,000		$ 2,600,000
Debt Instrument, Convertible, Number of Equity Instruments | shares			9,600
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.00027		$ 0.00027
Convertible Debentures [Member] | Reverse Stock Splits [Member]
Short-term Debt [Line Items]
Long-term Debt, Gross	$ 5,600,000		$ 5,600,000
Debt Instrument, Convertible, Number of Equity Instruments | shares			108.5
Debt Instrument, Convertible, Conversion Price | $ / shares	$ 0.052		$ 0.052
NonConvertible Debentures [Member]
Short-term Debt [Line Items]
Long-term Debt, Gross	$ 4,500,000		$ 4,500,000

Related Party Transactions (Det

Related Party Transactions (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Related Party Transaction [Line Items]
Insurance services revenue	$ 51,229		$ 51,229
Alcimede LLC [Member]
Related Party Transaction [Line Items]
Consulting fees	$ 100,000	$ 100,000	300,000	$ 300,000
InnovaQor [Member]
Related Party Transaction [Line Items]
Working capital			$ 200,000

Schedule of Lease-related Asset

Schedule of Lease-related Assets and Liabilities (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Finance And Operating Lease Obligations
Operating Lease, Right-of-Use Asset	$ 877,412	$ 1,000,272
Finance Lease, Right-of-Use Asset, after Accumulated Amortization	220,461	249,985
Lease assets	1,097,873	1,250,257
Operating Lease, Liability, Current	237,026	172,952
Finance Lease, Liability, Current	220,461	249,985
Operating Lease, Liability, Noncurrent	640,386	827,320
Total lease liabilities	$ 1,097,873	$ 1,250,257
Weighted-average remaining term: Operating leases	3 years 6 months	4 years 2 months 1 day
Weighted-average remaining term: Finance leases	0 years	0 years
Weighted-average discount rate: Operating leases	13.00%	13.00%
Weighted-average discount rate: Finance leases	4.90%	4.90%

Schedule of Information Related

Schedule of Information Related to Lease Expense for Finance and Operating Leases (Details) - USD ($)		3 Months Ended		9 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Finance And Operating Lease Obligations
Depreciation/amortization of leased assets					$ 26,349
Interest on lease liabilities					9,455
Short-term Lease, Cost	[1]	44,342	49,196	151,025	219,138
Total lease expense		$ 44,342	$ 49,196	$ 151,025	$ 254,942
[1]	Expenses are included in general and administrative expenses in the consolidated statements of operations.

Schedule of Supplemental Cash F

Schedule of Supplemental Cash Flow Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Finance And Operating Lease Obligations
Operating cash flows for operating leases	$ 168,923	$ 98,374
Operating cash flows for finance leases		9,455
Financing cash flows for finance lease payments	$ 29,524	$ 200,709

Schedule of Future Minimum Rent

Schedule of Future Minimum Rentals Under Right-to-use Operating and Finance Leases (Details) - USD ($)	Sep. 30, 2021	Jun. 30, 2021
Finance And Operating Lease Obligations
Twelve months ended June 30, 2022, Right-to-Use Operating Leases	$ 337,357
Twelve months ended June 30, 2022, Finance Leases		$ 224,252
Twelve months ended June 30, 2023, Right-to-Use Operating Leases	307,082
Twelve months ended June 30, 2023, Finance Leases
Twelve months ended June 30, 2024, Right-to-Use Operating Leases	217,839
Twelve months ended June 30, 2024, Finance Leases
Twelve months ended June 30, 2025, Right-to-Use Operating Leases	223,795
Twelve months ended June 30, 2025, Finance Leases
Twelve months ended June 30, 2026, Right-to-Use Operating Leases	18,650
Twelve months ended June 30, 2026, Finance Leases
Thereafter, Right-to-Use Operating Leases
Thereafter, Finance Leases
Total, Right-to-Use Operating Leases	1,104,723
Total, Finance Leases		224,252
Less interest, Right-to-Use Operating Leases
Less interest, Finance Leases
Present value of minimum lease payments, Right-to-Use Operating Leases	1,104,723
Present value of minimum lease payments, Finance Leases		224,252
Less current portion of lease obligations, Finance Leases	(227,311)	(3,791)
Lease obligations, net of current portion, Finance Leases	$ 877,412	$ 220,461

Finance and Operating Lease O_3

Finance and Operating Lease Obligations (Details Narrative) $ in Millions	Sep. 30, 2021USD ($)
Finance And Operating Lease Obligations
Future minimum lease payments and accrued interest	$ 0.2

Schedule of Fair Value of Asset

Schedule of Fair Value of Assets and Liabilities Measured on Recurring Basis (Details) - USD ($)	Sep. 30, 2021	Dec. 31, 2020
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total	$ 9,471,408	$ 455,336
Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total
Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total	9,471,408	455,336
InnovaQor Series B Preferred Stock [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total	9,016,072
InnovaQor Series B Preferred Stock [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total
InnovaQor Series B Preferred Stock [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total
InnovaQor Series B Preferred Stock [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total	9,016,072
Embedded Conversion Options [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total	455,336	455,336
Embedded Conversion Options [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total
Embedded Conversion Options [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total
Embedded Conversion Options [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Total	$ 455,336	$ 455,336

Fair Value Measurements (Detail

Fair Value Measurements (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Derivative Liability, Current	$ 455,336		$ 455,336		$ 455,336
Percentage of market price			85.00%
Fair Value Conversion Option			$ 0
Dividends	$ 259,200,000		$ 408,500,000	$ 59,800,000
Derivative [Member] | Minimum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.04%	0.09%	0.04%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	25.00%		25.00%	134.30%
Derivative [Member] | Minimum [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions measurement input weighted average remaining term		3 months
Derivative [Member] | Maximum [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	0.55%	0.12%	0.55%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	574.00%	208.20%
Derivative [Member] | Maximum [Member] | Measurement Input, Expected Term [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Fair value assumptions measurement input weighted average remaining term	3 years	1 year 5 months 26 days	3 years

Schedule of Warrants Activity (

Schedule of Warrants Activity (Details)	9 Months Ended
	Sep. 30, 2021USD ($)$ / sharesshares
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares of Common Stock Issuable for Warrants, expiration of warrants | $	$ (44,078,213)
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Number of Shares of Common Stock Issuable for Warrants, Beginning Balance | shares	4,571,165
Weighted average exercise price, Beginning Balance	$ 19.99
Number of Shares of Common Stock Issuable for Warrants, issuance of warrants | $	$ 47,500,000
Weighted average exercise price issuance of warrants	$ 0.007
Weighted average exercise price expiration of warrants	$ (0.3110)
Increase in number of shares of common stock issuable under warrants during the period as a result of down round provisions | shares	182,655,951,726
Number of Shares of Common Stock Issuable for Warrants, Ending Balance | shares	182,663,835,038
Weighted average exercise price, Ending Balance	$ 0.00043

Stockholders_ Deficit (Details

Stockholders’ Deficit (Details Narrative)	Oct. 28, 2021shares	Sep. 30, 2021$ / sharesshares	Aug. 10, 2021shares	Jun. 25, 2021shares	Sep. 30, 2020$ / sharesshares	Jun. 30, 2020USD ($)$ / sharesshares	Nov. 10, 2021shares	Sep. 30, 2021USD ($)$ / sharesshares	Jun. 30, 2021USD ($)	Sep. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2020$ / sharesshares	Sep. 30, 2021USD ($)$ / sharesshares	Sep. 30, 2020USD ($)$ / sharesshares	Nov. 07, 2021	Nov. 05, 2021shares	Nov. 04, 2021shares	Aug. 27, 2021$ / sharesshares	Dec. 31, 2020$ / sharesshares	Aug. 31, 2020shares	May 05, 2020shares	May 04, 2020shares
Class of Stock [Line Items]
Common stock shares authorized		10,000,000,000						10,000,000,000				10,000,000,000			50,000,000,000			10,000,000,000
Common stock par value | $ / shares		$ 0.0001						$ 0.0001				$ 0.0001						$ 0.0001
Preferred stock shares authorized		5,000,000						5,000,000				5,000,000
Preferred stock par value | $ / shares		$ 0.01						$ 0.01				$ 0.01
Gain on extinguishment of debt | $								$ 1,027,000		$ 389,864		$ 1,027,000	$ 389,864
Warrant dividend value | $								$ 259,200,000				408,500,000	59,800,000
Proceeds from Issuance of Preferred Stock | $												$ 5,000,000
Number of share issue				14,000				950
Common Stock, Shares, Outstanding		4,777,350,000						4,777,350,000				4,777,350,000						39,648
Common Stock, Shares, Issued		4,777,350,000						4,777,350,000				4,777,350,000						39,648
Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price | $ / shares		$ 2,992,125						$ 2,992,125				$ 2,992,125
Warrants and Rights Outstanding, Term		5 years						5 years				5 years
Warrants and rights outstanding, term		6 months						6 months				6 months
March 2017 Debentures [Member]
Class of Stock [Line Items]
Warrants exercise price | $ / shares		$ 0.00027						$ 0.00027				$ 0.00027
Number of warrants exercisable into common stock												66,500,000,000
Two Thousand And Seven Equity Plan [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Units												26
Subsequent Event [Member]
Class of Stock [Line Items]
Common stock shares authorized															50,000,000,000	10,000,000,000
Number of share issue							8,700,000,000
Common Stock, Shares, Outstanding							476,200,000,000
Warrants maturity date														Mar. 21, 2024
Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Warrant measurement input		0.05						0.05				0.05
Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Warrant measurement input		230						230				230
Board Of Directors [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		5,000,000						5,000,000				5,000,000
Preferred Stock, Shares Issued		10,000						10,000				10,000
Exchange Agreement [Member]
Class of Stock [Line Items]
Number of shares issued upon conversion, value																					250,000
Exchange Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]
Class of Stock [Line Items]
Equity Securities, FV-NI, Measurement Input		0.41						0.41				0.41
Exchange Agreement [Member] | Measurement Input, Price Volatility [Member]
Class of Stock [Line Items]
Equity Securities, FV-NI, Measurement Input		364						364				364
Exchange Agreement [Member] | Measurement Input, Expected Term [Member]
Class of Stock [Line Items]
Equity securities measurement input term												3 years
Exchange Agreement [Member] | Diamantis [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																	95,000,000
Warrants exercise price | $ / shares		$ 0.00027						$ 0.00027				$ 0.00027
Preferred Stock [Member]
Class of Stock [Line Items]
Number of share issue											250,000
Warrant [Member]
Class of Stock [Line Items]
Warrant dividend value | $								$ 300,000				$ 300,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)												182,655,951,726
Proceeds from Issuance of Warrants | $												$ 47,500,000
Warrant [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Warrant dividend value | $								$ 300,000				$ 300,000
Warrant [Member] | Exchange Agreement [Member] | Diamantis [Member]
Class of Stock [Line Items]
Common stock shares authorized																	47,500,000
Warrants exercise price | $ / shares																	$ 0.007
Warrants exercisable term												three-year
Warrant [Member] | Exchange Agreements [Member]
Class of Stock [Line Items]
Number of warrants exercisable into common stock												1,200,000,000
Warrants [Member]
Class of Stock [Line Items]
Number of warrants issued												4 years 7 months 13 days
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted												182,700,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)												182,700,000,000
March Warrants [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Period Increase (Decrease)												177,800,000,000
Series B Warrant [Member] | March 2017 Debentures [Member]
Class of Stock [Line Items]
Number of warrants exercisable into common stock												42,600,000,000
Series B Warrants [Member] | March 2017 Debentures [Member]
Class of Stock [Line Items]
Number of warrants exercisable into common stock												68,700,000,000
Series C Warrant [Member] | March 2017 Debentures [Member]
Class of Stock [Line Items]
Warrants and Rights Outstanding, Term		5 years						5 years				5 years
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		1,750,000						1,750,000				1,750,000						1,750,000
Preferred stock par value | $ / shares		$ 0.01						$ 0.01				$ 0.01						$ 0.01
Preferred Stock, Shares Outstanding		1,750,000						1,750,000				1,750,000						1,750,000
Preferred Stock, Shares Issued		1,750,000						1,750,000				1,750,000						1,750,000
Series H Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		14,202						14,202				14,202
Preferred stock par value | $ / shares																		$ 0.01
Preferred Stock, Shares Outstanding		10						10				10						10
Number of shares issued upon conversion, value		37,000,000						37,000,000				37,000,000
Series H Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Number of shares issued upon conversion, value		1						1				1
Series L Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		250,000						250,000				250,000						250,000
Preferred stock par value | $ / shares		$ 0.01						$ 0.01				$ 0.01						$ 0.01
Preferred Stock, Shares Outstanding		250,000						250,000				250,000						250,000
Preferred Stock, Shares Issued		250,000						250,000				250,000						250,000
Series L Preferred Stock [Member] | Exchange Agreement [Member] | Alcimede LLC [Member]
Class of Stock [Line Items]
Number of shares issued upon conversion, value																				250,000
Series M Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		30,000						30,000				30,000						30,000
Preferred stock par value | $ / shares		$ 0.01						$ 0.01				$ 0.01						$ 0.01
Preferred Stock, Shares Outstanding		20,810						20,810				20,810						22,000
Exchange of shares					570
Debt and accrued interest | $													$ 22,000,000
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt | $												$ 600,000
Stock Issued During Period, Shares, Conversion of Units												619.65
Debt Conversion, Converted Instrument, Shares Issued												95,000,000
Preferred Stock, Shares Issued		20,810						20,810				20,810						22,000
Conversion of Stock, Shares Issued												450,000
Series M Preferred Stock [Member] | Diamantis [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		5,000,000			30,000			5,000,000		30,000		5,000,000	30,000
Preferred stock par value | $ / shares					$ 1,000					$ 1,000			$ 1,000
Gain on extinguishment of debt | $						$ 18,800,000
Exchange of shares						22,000
Preferred stock, stated value | $ / shares						$ 0.01					$ 0.01
Warrant dividend value | $													$ 3,200,000
Debt and accrued interest | $													$ 18,800,000
Stock Issued During Period, Shares, Conversion of Convertible Securities												610.65
Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt | $												$ 600,000
Stock Issued During Period, Shares, Conversion of Units												450,000
Series M Preferred Stock [Member] | Exchange Agreement [Member] | Diamantis [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																	570
Series M Preferred Stock [Member] | Warrant [Member] | Exchange Agreement [Member]
Class of Stock [Line Items]
Proceeds from Issuance of Warrants | $												$ 47,500,000
Series N Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		50,000						50,000				50,000						50,000
Preferred stock par value | $ / shares		$ 0.01						$ 0.01				$ 0.01						$ 0.01
Preferred Stock, Shares Outstanding		11,084						11,084				11,084						29,434
Stock Issued During Period, Shares, Conversion of Units												18,355.5	131
Equity, Fair Value Adjustment | $										$ 1,650,000			$ 300,000
Interest Expense | $													2,300,000
Stock Issued During Period, Value, Conversion of Units | $													$ 100,000
Preferred Stock, Shares Issued		11,084			589			11,084		589		11,084	589					29,434
Conversion of Stock, Shares Issued													589
Series N Preferred Stock [Member] | Exchange and Redemption Agreement [Member]
Class of Stock [Line Items]
Gain on extinguishment of debt | $													$ 400,000
Series N Preferred Stock [Member] | Preferred Stock [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Outstanding		11,084						11,084				11,084
Series O Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock shares authorized		10,000						10,000				10,000						10,000
Preferred stock par value | $ / shares		$ 0.01						$ 0.01				$ 0.01						$ 0.01
Preferred Stock, Shares Outstanding		5,500						5,500				5,500						0
Preferred stock, stated value | $ / shares		$ 1,000						$ 1,000				$ 1,000
Stock Issued During Period, Shares, Conversion of Units			1,100
Preferred Stock, Shares Issued		5,500	5,500					5,500				5,500						0
Proceeds from Issuance of Preferred Stock | $								$ 2,500,000	$ 2,500,000			$ 5,000,000
Dividend rate		10.00%
Debt conversion description												The conversion price is equal to 90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date. Holders of the Series O Preferred Stock are prohibited from converting Series O Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after notice to the Company.
Series O Preferred Stock [Member] | Subsequent Event [Member] | Maximum [Member]
Class of Stock [Line Items]
Number of share issue	4,400
Series O Preferred Stock [Member] | Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Preferred Stock, Shares Issued			4,400
Series O Preferred Stock [Member] | Second Securities Purchase Agreement [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Units		550
Preferred Stock, Shares Issued		1,100						1,100				1,100
Series K Preferred Stock [Member] | Exchange Agreement [Member] | Alcimede LLC [Member]
Class of Stock [Line Items]
Number of shares issued upon conversion, value																				250,000
Series I-1 and Series I-2 Preferred Stock [Member] | Exchange and Redemption Agreement [Member]
Class of Stock [Line Items]
Preferred stock shares authorized																			30,435.52
Warrant dividend value | $													$ 3,700,000
Series N Preferred Stocks [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Units												18,350.1
Stock Issued During Period, Value, Conversion of Units | $												$ 18,400,000
Preferred Stock, Shares Issued		4,700,000,000						4,700,000,000				4,700,000,000
Series O Preferred Stock Two [Member] | Subsequent Event [Member]
Class of Stock [Line Items]
Number of share issue	2,200
Series I-2 Preferred Stock [Member]
Class of Stock [Line Items]
Stock Issued During Period, Shares, Conversion of Units													236.3
Conversion of Stock, Shares Issued													313

Schedule of Supplemental Disclo

Schedule of Supplemental Disclosure of Cash Flow Information (Details) - USD ($)	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Supplemental Cash Flow Elements [Abstract]
Cash paid for interest		$ 64,454
Cash paid for income taxes	281,025
Preferred stock of InnovaQor received from the sale of HTS and AMSG	9,117,500
Net liabilities of HTS and AMSG transferred to InnovaQor	2,227,152
Settlement of liability with InnovaQor preferred stock	60,714
Issuance of notes payable in settlement of accounts payable and accrued expenses	2,352,961
Series I-2 Preferred Stock converted into common stock		277,994
Exchange of Series K Preferred Stock for Series L Preferred Stock		(2,500)
Issuance of Series L Preferred Stock		2,500
Issuance of Series M Preferred Stock in exchange for related party loans and accrued interest		22,000,000
Loans and accrued interest exchanged for Series M Preferred Stock		(18,849,632)
Deemed dividend from exchange of loans and accrued interest for Series M Preferred Stock		3,150,368
Series M Preferred Stock converted/exchanged into common stock	1,189,650
Deemed dividends from issuance of common stock warrants under exchange agreement	341,525
Issuance of Series N Preferred Stock in exchange for debentures, accrued interest and Series I-1 and Series I-2 Preferred Stock		30,435,519
Debentures, accrued interest and Series I-1 and Series I-2 Preferred Stock exchanged for Series N Preferred Stock		(19,342,322)
Series N Preferred Stock converted into common stock	18,355,507	58
Deemed dividends from the issuance of Series N Preferred Stock		3,720,718
Deemed dividends for trigger of down round provisions	408,509,361	59,824,232
Deemed dividends from extension of common stock warrants	291,592
Original issue discounts on debt	$ 52,836	$ 108,958

Commitments and Contingencies (

Commitments and Contingencies (Details Narrative) - USD ($)

Oct. 31, 2021

Sep. 15, 2021

Sep. 14, 2021

Feb. 08, 2017

Jan. 24, 2017

Feb. 28, 2021

May 31, 2020

Nov. 30, 2019

Aug. 31, 2019

Jun. 30, 2019

May 31, 2019

Jun. 30, 2021

Sep. 30, 2021

Sep. 30, 2020

Dec. 31, 2021

Feb. 29, 2020

Dec. 07, 2016

Nov. 30, 2016

Sep. 27, 2016

Income tax liability

$ 1,000,000

Income Taxes Receivable

$ 300,000

$ 900,000

Repayments of Debt

$ 920,000

Interest Payable

200,000

Repayments of Notes Payable

350,508

1,552,748

Repayments of Related Party Debt

360,000

4,187,387

Settlement Agreement [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 3,201

$ 109,739

Repayments of Related Party Debt

$ 52,941

Settlement Agreement [Member] | Two Monthly [Member]

Repayments of Related Party Debt

$ 900,000

Subsequent Event [Member]

Settlement amount

$ 425,000

Febuary Two Thousand And Twenty Two [Member]

Legal Fees

50,000

August Fifteen Two Thousand And Twenty One [Member] | Settlement Agreement [Member]

Litigation Settlement, Amount Awarded from Other Party

32,922

Holders of Tegal Notes [Member]

Equiment lease outstanding balance

$ 341,612

Interest Payable

$ 43,000

Repayments of Notes Payable

50,055

MrDiamantis [Member]

Repayments of Debt

1,500,000

Interest Payable

300,000

$ 200,000

Payment in settlement of judgment

$ 2,158,168

$ 700,000

Penality Interest rate

20.00%

MrDiamantis [Member] | Promissory Note [Member]

Due to Related Parties

$ 2,000,000

Florida Department of Revenue [Member]

Income Tax Examination, Penalties and Interest Accrued

$ 900,000

Due to Related Parties

$ 400,000

DeLage Landen Financial Services, Inc. [Member]

Litigation Settlement, Amount Awarded from Other Party

$ 1,000,000

Implicit interest rate

4.97%

Equiment lease outstanding balance

200,000

2015 Federal Income Tax Audit [Member]

Income tax liability

800,000

Income Taxes Receivable

1,100,000

Repayments of Debt

300,000

EPIC Reference Laboratories, Inc. [Member]

Settlement Liabilities, Current

$ 1,100,000

Litigation Settlement, Amount Awarded from Other Party

$ 155,000

Medytox Solutions, Inc [Member]

Loss Contingency, Damages Sought, Value

$ 2,030,000

Shared Medical Services, Inc [Member]

Loss Contingency, Damages Paid, Value

$ 90,000

Legal Fees

$ 100,000

CHSPCS [Member]

Payment in settlement of judgment

$ 130,000

Settlement amount

$ 592,650

Morrison Management Specialists, Inc [Member]

Settlement amount

$ 194,455

Newstat, PLLC [Member]

Settlement amount

$ 190,600

Schedule of Discontinued Operat

Schedule of Discontinued Operation of Balance Sheet and Operation Statement (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash					$ 31,430
Accounts receivable, net					151,363
Prepaid expenses and other current assets					1,717
Current assets classified as held for sale					184,510
Property and equipment, net					685
Deposits	5,014		5,014		100,014
Right of use assets					100,116
Non-current assets classified as held for sale	5,014		5,014		200,815
Accounts payable and checks issued in excess of bank balance	1,111,557		1,111,557		1,911,378
Accrued expenses	336,410		336,410		1,642,950
Current portion of right-of-use operating lease obligation					91,166
Current portion of notes payable					168,751
Current liabilities classified as held for sale	1,447,967		1,447,967		3,814,245
Note payable					69,267
Right-of-use operating lease obligation					8,950
Liabilities classified as held for sale					78,217
Revenue from services		$ 174,941	216,941	$ 437,560
Cost of services		390	2,386	11,379
Gross profit		174,551	214,555	426,181
Operating expenses	(31,388)	(300,149)	(677,539)	(616,693)
Other income (expense)		(40,582)	39,193	26,219
Gain on sale	576,787		11,303,939
Provision for income taxes
Income (loss) from discontinued operations	545,399	(166,180)	10,880,148	(164,293)
Advanced Molecular Services Group And Health Technology Solutions Inc [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash					31,294
Accounts receivable, net					151,363
Prepaid expenses and other current assets					1,717
Current assets classified as held for sale					184,374
Property and equipment, net					685
Deposits
Right of use assets
Non-current assets classified as held for sale					685
Accounts payable and checks issued in excess of bank balance					726,220
Accrued expenses					1,308,283
Current portion of right-of-use operating lease obligation
Current portion of notes payable					168,751
Current liabilities classified as held for sale					2,203,254
Note payable					69,267
Right-of-use operating lease obligation
Liabilities classified as held for sale					69,267
Revenue from services		174,941	216,941	437,119
Cost of services		390	2,386	11,379
Gross profit		174,551	214,555	425,740
Operating expenses		(258,710)	(551,296)	(509,989)
Other income (expense)		(9,636)	(9,577)	(61,067)
Gain on sale	576,787		11,303,939
Provision for income taxes
Income (loss) from discontinued operations	576,787	(93,795)	10,957,621	(145,316)
EPIC Reference Labs, Inc. [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Cash					136
Accounts receivable, net
Prepaid expenses and other current assets
Current assets classified as held for sale					136
Property and equipment, net
Deposits	5,014		5,014		100,014
Right of use assets					100,116
Non-current assets classified as held for sale	5,014		5,014		200,130
Accounts payable and checks issued in excess of bank balance	1,111,557		1,111,557		1,185,158
Accrued expenses	336,410		336,410		334,667
Current portion of right-of-use operating lease obligation					91,166
Current portion of notes payable
Current liabilities classified as held for sale	1,447,967		1,447,967		1,610,991
Note payable
Right-of-use operating lease obligation					8,950
Liabilities classified as held for sale					$ 8,950
Revenue from services				441
Cost of services
Gross profit				441
Operating expenses	(31,388)	(41,439)	(126,243)	(106,704)
Other income (expense)		(30,946)	48,770	87,286
Gain on sale
Provision for income taxes
Income (loss) from discontinued operations	$ (31,388)	$ (72,385)	$ (77,473)	$ (18,977)

Discontinued Operations (Detail

Discontinued Operations (Details Narrative) - USD ($)	Jun. 25, 2021	Sep. 30, 2021	Jun. 30, 2020	Sep. 30, 2021	Dec. 31, 2020
Number of shares converted	14,000	950
Long-term Debt					$ 12,700,000
Sale of Stock, Number of Shares Issued in Transaction		950
Liabilities		$ 58,009,546		$ 58,009,546	$ 61,279,843
Stock Issued During Period, Value, New Issues			$ 2,500
Preferred Stock [Member]
Number of shares converted			250,000
Stock Issued During Period, Value, New Issues			$ 2,500
A M S G [Member]
Gain on Sale of Investments		600,000
Liabilities		$ 2,200,000		2,200,000
H T S [Member]
Gain on Sale of Investments				$ 11,300,000
Series B Non Voting Convertible Preferred Stock [Member]
Number of shares converted	14,950
Series B Preferred Stock [Member]
Preferred stock, stated value		$ 1,000		$ 1,000
Preferred Stock, Dividend Rate, Percentage				90.00%
Debt Instrument, Interest Rate During Period				4.99%
Long-term Debt		$ 9,100,000		$ 9,100,000
Sale of Stock, Consideration Received on Transaction				$ 9,100,000
InnovaQor Series B Preferred Stock [Member] | Preferred Stock [Member]
Number of shares converted				100
Stock Issued During Period, Value, New Issues				$ 60,714

Schedule of Dilutive Effect of

Schedule of Dilutive Effect of Various Potential Common Shares (Details) - shares	Nov. 10, 2021	Sep. 30, 2021	Sep. 30, 2020
Subsequent Event [Line Items]
Total dilutive potential common shares, including outstanding common stock		282,099,578,443	700,428
Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Total dilutive potential common shares, including outstanding common stock		89,770,798,934	313,808
Warrant [Member]
Subsequent Event [Line Items]
Total dilutive potential common shares, including outstanding common stock		182,663,835,039	335,461
Share-based Payment Arrangement, Option [Member]
Subsequent Event [Line Items]
Total dilutive potential common shares, including outstanding common stock		26	26
Subsequent Event [Member]
Subsequent Event [Line Items]
Total dilutive potential common shares, including outstanding common stock	476,249,682,985
Subsequent Event [Member] | Common Shares Outstanding [Member]
Subsequent Event [Line Items]
Total dilutive potential common shares, including outstanding common stock	13,491,000,000
Subsequent Event [Member] | Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Total dilutive potential common shares, including outstanding common stock	174,319,763,738
Subsequent Event [Member] | Warrant [Member]
Subsequent Event [Line Items]
Total dilutive potential common shares, including outstanding common stock	273,995,752,554
Subsequent Event [Member] | Convertible Debt [Member]
Subsequent Event [Line Items]
Total dilutive potential common shares, including outstanding common stock	14,443,166,667
Subsequent Event [Member] | Share-based Payment Arrangement, Option [Member]
Subsequent Event [Line Items]
Total dilutive potential common shares, including outstanding common stock	26

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - USD ($)

Nov. 07, 2021

Oct. 28, 2021

Oct. 28, 2021

Sep. 30, 2021

Jun. 25, 2021

Nov. 10, 2021

Sep. 30, 2021

Jun. 30, 2021

Jun. 30, 2020

Sep. 30, 2021

Sep. 30, 2020

Nov. 05, 2021

Nov. 04, 2021

Nov. 03, 2021

Dec. 31, 2020

Subsequent Event [Line Items]

Common stock, authorized shares

10,000,000,000

10,000,000,000

10,000,000,000

50,000,000,000

10,000,000,000

Issuance of Series L Preferred Stock, shares

14,000

950

Stock Issued During Period, Value, New Issues

$ 2,500

Proceeds from Issuance of Preferred Stock and Preference Stock

$ 5,000,000

Long-term Debt

$ 12,700,000

Preferred stock shares authorized

5,000,000

5,000,000

5,000,000

Board Of Directors [Member]

Subsequent Event [Line Items]

Preferred stock shares authorized

5,000,000

5,000,000

5,000,000

Series O Preferred Stock [Member]

Subsequent Event [Line Items]

Proceeds from Issuance of Preferred Stock and Preference Stock

$ 2,500,000

$ 2,500,000

$ 5,000,000

Preferred stock shares authorized

10,000

10,000

10,000

10,000

Dividend percentage

10.00%

Series N Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock shares authorized

50,000

50,000

50,000

50,000

Subsequent Event [Member]

Subsequent Event [Line Items]

Common stock, authorized shares

50,000,000,000

10,000,000,000

Issuance of Series L Preferred Stock, shares

8,700,000,000

Subsequent Event [Member] | Novermber Two Thousand Twenty One Exchange And Amendment Agreements [Member]

Subsequent Event [Line Items]

Long-term Debt

$ 1,400,000

Subsequent Event [Member] | Series O Preferred Stock [Member] | Maximum [Member]

Subsequent Event [Line Items]

Issuance of Series L Preferred Stock, shares

4,400

Subsequent Event [Member] | Series O Preferred Stock [Member] | October 28 Agreement [Member]

Subsequent Event [Line Items]

Issuance of Series L Preferred Stock, shares

2,200

Stock Issued During Period, Value, New Issues

$ 2,000,000

Proceeds from Issuance of Preferred Stock and Preference Stock

$ 2,000,000

Subsequent Event [Member] | Series O Preferred Stock [Member] | October 28 Agreement [Member] | Maximum [Member]

Subsequent Event [Line Items]

Issuance of Series L Preferred Stock, shares

4,400

Subsequent Event [Member] | Series P Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock shares authorized

5,000,000

Preferred stock, stated value

$ 1,000

Dividend percentage

10.00%

Debt instrument description

The conversion price is equal to 90% of the lowest VWAP during the 10 trading days immediately prior to the conversion date. Holders of the Series P Preferred Stock are prohibited from converting Series P Preferred Stock into shares of common stock if, as a result of such conversion, the holder, together with its affiliates, would own more than 9.99% of the total number of shares of common stock then issued and outstanding. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99%, provided that any increase in such percentage shall not be effective until 61 days after notice to the Company.

Subsequent Event [Member] | Series P Preferred Stock [Member] | Board Of Directors [Member]

Subsequent Event [Line Items]

Preferred stock shares authorized

30,000

Subsequent Event [Member] | Series P Preferred Stock [Member] | Novermber Two Thousand Twenty One Exchange And Amendment Agreements [Member]

Subsequent Event [Line Items]

Stock Issued During Period, Shares, Conversion of Convertible Securities

8,545

Subsequent Event [Member] | Series N Preferred Stock [Member]

Subsequent Event [Line Items]

Conversion of stock share converted

2,495.84

Number of conversion share issueed value

$ 2,500,000

PPP Notes [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Principal amount

$ 800,000

Promissory Notes Payable [Member] | Subsequent Event [Member] | Novermber Two Thousand Twenty One Exchange And Amendment Agreements [Member] | Warrants [Member]

Subsequent Event [Line Items]

Long-term Debt

$ 1,100,000

NonConvertible Debentures [Member] | Subsequent Event [Member] | Novermber Two Thousand Twenty One Exchange And Amendment Agreements [Member]

Subsequent Event [Line Items]

Long-term Debt

4,500,000

Debenture [Member] | Subsequent Event [Member] | Novermber Two Thousand Twenty One Exchange And Amendment Agreements [Member]

Subsequent Event [Line Items]

Long-term Debt

8,200,000

Interest Expense, Subordinated Notes and Debentures

$ 3,300,000